key: cord-0017721-curmgjh1
authors: Huda, Md Nurul; Nafiujjaman, Md; Deaguero, Isaac G.; Okonkwo, Jude; Hill, Meghan L.; Kim, Taeho; Nurunnabi, Md
title: Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications
date: 2021-05-14
journal: ACS Biomater Sci Eng
DOI: 10.1021/acsbiomaterials.1c00217
sha: baecae459a74af6ce7ee2d680918cbb6c439a878
doc_id: 17721
cord_uid: curmgjh1

[Image: see text] Exosomes are cell-derived vesicles containing heterogeneous active biomolecules such as proteins, lipids, mRNAs, receptors, immune regulatory molecules, and nucleic acids. They typically range in size from 30 to 150 nm in diameter. An exosome’s surfaces can be bioengineered with antibodies, fluorescent dye, peptides, and tailored for small molecule and large active biologics. Exosomes have enormous potential as a drug delivery vehicle due to enhanced biocompatibility, excellent payload capability, and reduced immunogenicity compared to alternative polymeric-based carriers. Because of active targeting and specificity, exosomes are capable of delivering their cargo to exosome-recipient cells. Additionally, exosomes can potentially act as early stage disease diagnostic tools as the exosome carries various protein biomarkers associated with a specific disease. In this review, we summarize recent progress on exosome composition, biological characterization, and isolation techniques. Finally, we outline the exosome’s clinical applications and preclinical advancement to provide an outlook on the importance of exosomes for use in targeted drug delivery, biomarker study, and vaccine development.

With recent development and progress, biomarkers are an emerging tool for drug discovery and development. Given that the exosome embodies various proteins and lipids that are cell derived, these specific proteins, receptors, signaling molecules, and lipids can be identified and potentially used for diagnostic measures of abnormalities on the cellular level when compared with a healthy control. 1 Therefore, exosome-mediated detection technologies have emerging potential in the early stage disease diagnosis field. Early detection via biomarker identification is considered a robust tool for efficient treatment of various chronic diseases such as cancer, autoimmune, infectious, and inflammatory diseases. 2−4 Besides, biomarkers are being widely used as diagnostic tools, personalized medicine platforms, and substitute end points for clinical research. 5 Over the past decade, there have been many exciting developments in drug delivery. Synthetic biopolymers stand out among these innovations due to their ability to act as a drug delivery platform with improved abilities in drug targeting and controlled release. 6 Also, a range of exosome-mediated drug formulations is being developed and currently undergoing preclinical and clinical trials. Unfortunately, drug-loaded synthetic polymers will opsonize with other biomolecules (protein) in the bloodstream which can result in three distinct issues: toxicity, immunogenicity, and mononuclear phagocyte system (MPS) rapid clearance. 7, 8 In the hopes of addressing these issues, the exosome has been singled out as a potential candidate as a bioinspired, bioengineered, and biomimetic drug delivery solution. 9, 10 Exosomes usually range from 30 to 150 nm. The intraluminal vesicle (ILV) is a circular lipid bilayer vesicle released from cells that differs from other extracellular vesicles such as microvesicles and apoptotic bodies, in composition and biogenesis. 11, 12 First described as small vesicles by which maturating sheep reticulocytes discard obsolete cellular components, 13, 14 further studies have shown that exosomes and other secreted extracellular vesicles are the prominent and universal form of cell-to-cell communication. 15 When exosomes are released, they are immediately internalized by surrounding cells or enter systemic circulation for intercellular communication. 16 Exosome secretion is a constitutive mechanism involved in both pathological and physiological conditions, regulating exosome surface markers and contents. 1, 17 Exosomes can transport biologically active molecules, including proteins, fragmented DNA, antigens, and nucleic acids that regulate gene expression and cellular function in target cells. 18−22 As such, exosomes mediate autocrine, paracrine, and endocrine effects, classifying them as potential therapeutics. 18 For example, mesenchymal stem cells (MSCs) and other progenitor cells used in cell therapy mediated cytoprotective, angiogenic, and regenerative effects that can be recapitulated by the exosomes they release. 23 Indeed, exosomes have been found and investigated in numerous bodily fluids, including bile acid, blood, breast milk, urine, cerebrospinal fluid, and saliva, suggesting that exosomes play a prominent role in physiological regulation response and disease progression. 1,11,24−26 Recently, exosomes' pathophysiological role in diseases, especially cancers, neurodegenerative, inflammatory, and infectious diseases, has emerged. 26−29 Exosomes function as diagnostic biomarkers, imaging tools, therapeutic targets, tissue repairing agents, and drug delivery platforms and can be used in vaccine development. This would eventually lead to preclinical and clinically trials as avenues of new investigation as a result of their unique biological and pathophysiological characteristics. 30−35 However, thus far, there is no review currently available about the progress of exosome research and potential applications in a clinical setting. In this review, we have laid out a comprehensive study on the status of exosome clinical trials and their preclinical application to various diseases. More information on exosome classification, biological composition, relevant markers can be found at http://www.isev.org (International Society for Extracellular Vesicles), http://microvesicles.org (Vesiclepedia, a compendium for EVs with continuous community annotation), 36 http://www.exocarta.org (ExoCarta, a webbased compendium of exosomal cargo), 37 and http://exrna.org (extracellular RNA communication program). Also, we state how exosome surface engineering can act as translational medicine agents due to advancement in bioengineering techniques such as cationic pullulan, cationic linkers (DBCO-amine/dye), aptamer-based DNA tether, and click chemistry. 38−41 2. EXOSOME COMPOSITION, BIOGENESIS, AND MECHANISM OF ACTION About 98% of all potential therapeutic medicines related to central nervous system (CNS) diseases have failed to reach the market due to an inability to cross the blood−brain barrier (BBB). 42 While drug formulations have managed to overcome the barrier, 43, 44 they have their own drawbacks, including significant toxicity and rapid clearance by the mononuclear phagocyte system (MPS). 7 Similar immediate clearance phenomena are observed in animal models for targeted drug delivery, cell therapy, and tumor therapy. 45, 46 On the contrary, exosomes (30−150 nm) and cell origin vesicles offer intrinsic characteristics of an ideal drug delivery method for an intracellular platform. 47, 48 Exosomes as delivery vesicles provide (i) good tolerance in the body because of their wide distribution in bodily fluids (like milk, urine, blood, saliva, etc.), 4,50−53 (ii) proper internalization in distant cells, 54 (iii) reliable delivery of cargo such as proteins, 55 mRNA, 56 lipids, 57 drugs, 6 and nucleic acids, and (iv) an extended circulation halflife via i.v. injections. 58 Thus, naturally occurring exosomal intrinsic properties enable targeted delivery and diminish the rapid clearance of drugs. 59 −61 In Figure 1 , we illustrate what a typical exosome contains. From our understanding, the composition varies in its protein, lipid, and nucleic acid content depending on cell origin, cell homeostasis, and its current pathological condition. On their surface, exosomes carry immune regulatory molecules, membrane trafficking molecules, and tetraspanin. These molecules either help the exosome to bind or pass through the recipient membrane for delivering its cargo. Exosomes carry multiple forms of these molecules inside them, including nucleic acids, signaling molecules, chaperons, and enzymes to bring the message to the neighboring cells. These chemical messengers can both modulate cell physiology and carry information about any foreign invaders. Exosomes originating from immune cells can activate or inactivate T-cells, depending on immune cell physiological conditions. This is why we found multiple studies on exosome proteomics and lipidomics that explore exosome composition for either biomarker study or targeted drug delivery. Exosomes also play a crucial role in cell−cell communication using protein chaperones, cDNA, nucleic acid, and mRNA content to connect with neighboring and distant cells. 62 Exosomes deliver their protein, lipid, and cytoplasmic content to recipient cells through membrane fusion and modify physiological and pathological functions of targeted cells. 63 The exosome's cargo is determined by its cell origin, cell physiological condition, and intercellular release site. 1 Exosome biogenesis begins with early endosomal maturation to microvesicles (MVB) and late endosomes to exosomes, during which endosomal membrane transforms into intraluminal vesicles (ILVs) in the lumen of the organelles through multiple pathways. 64 The most studied endosomal pathways are associated with endosomal complexes ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III, and AAA ATPase Vps4 associated complex for transport. 65−68 In ESCRT RNAi screening, a total of 23 ESCRT and ESCRT-associated proteins have been identified in HeLa cells. 69 In another study after shRNA transfection, secreted exosome trapped with anti-CD63 beads and screen identified seven ESCRT proteins with a role in exosome secretion. 70 One research study showed that the depletion of both ESCRT-0 protein Hrs and ESCRT-1 protein STAM1 resulted in reduced exosome secretion. 69 On the contrary, knockdown of ESCRT-III and associated proteins like VSP4B, VTA1, and ALIX increased exosome secretion. 69 In the same study, after further investigation, the authors found that Hrs, TSG101, and STAM1 depletion decreased exosome secretion, whereas VPS4B knockdown increased production. Those proteins were purified by ultracentrifugation and analyzed via Western blot (WB) and qRT-PCR. 69−71 The endosomal membrane transiently recruited ESCRT proteins from the cytoplasm, where their function is to sort the transmembrane protein from MVB. ESCRT-0 binds with a ubiquitin-protein programmed for degradation, executing a sorting of MVB in the first set of steps. 62 Knockdown of ESCRT-0 protein Hrs from dendritic cells results in fewer exosomes secreted, which can be measured by the exosomal level of ubiquitinated proteins: TSG101 and VPS4B. 72 ESCRT-I and -II promote the budding process and start the enzymatic deubiquitous cargo protein before forming (ILVs) microvesicles in the intracellular compartment. 73 The ESCRT-3 complex drives the final stage of membrane invagination and separation. 74 An integral membrane protein of the lysosome has been suggested to play a role in exosome formation. A higher amount of exosome secretion was observed after transfection of COS cells with SIMPLE lipopolysaccharide-induced TNF factor (LITAF) and mutation of SIMPLE interfered with proper MVB formation. 75 Also, syndecans, the membrane proteins carrying heparan sulfate chains, are mediated by their binding to syntenin. Syntenin is a multivalent soluble protein that binds ALIX to build a link between syndecans and ESCRT machinery. 76 Another study determines that the syndecan− syntenin−ALIX mechanism in MCF-7 cells was responsible for 1−50% of the secreted exosomes. 77 In addition to proteins, lipids also play an essential role in vesicular transport, 78, 79 and both act intrinsically for vesicle transportation like membrane deformation, fission, and fusion. 80 The exosome membrane is enriched in sphingomyelin, tetraspanin, integrin, cholesterol, immune regulatory molecules, and ceramide, whereas inside it contains chaperons, mRNA, cDNA, and proteins. 49, 81, 82 Exosomes released from a cell are taken up through catherinindependent endocytosis or micropinocytosis by neighboring cells. 19,83−85 Once internalized by recipient cells, exosomes release their cargo, resulting in the altered regulation of the recipient cell's various biological functions. 86, 87 The biogenesis of exosomes is often described as either an ESCRT-dependent or ESCRT-independent mechanism, 88 but these pathways might interplay. 89 Current research also suggests that these pathways may work synergistically in the different subpopulations of exosomes depending on the origin of the various biogenesis machinery. 90 Phospholipids and sphingolipids are also involved in the formation of exosomes. 91−93 For example, following epidermal growth factor (EGF) stimulation, EGF receptor (EGFR) was not sorted into the ILVs of ESCRT-depleted cells, suggesting diversity in exosome formation pathways. 90 The late endosomal lipid marker, bismonoacylglycerophosphate (BMP), also known as lysobisphosphatidic acid (LBPA), was found to colocalize with EGF-containing exosomes. However, other studies have suggested that LBPA-carrying MVBs are distinct from EGF, provided that MVBs are developed after EGFR stimulation (EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular endosome subpopulation). 94 , 95 Multiple studies have been done on both ESCRT-dependent and -independent pathways of exosome biogenesis. 69,96−98 Finally, the comparatively smaller size and unified shape allow exosomes to successfully escape clearance by the MPS, prolonging their circulation time and implying their cell−cell communication superiority. Remember, the biogenesis pathways work synergistically, meaning that the subpopulation of exosomes depends on a different mechanism. The cell homeostasis and physiological conditions are also essential factors to consider, which control exosome release and secretion pathways. 99, 100 For example, silencing of ALIX protein modulates exosome cargo selection rather than affecting their secretion. Decreasing ALIX expression in shRNA-expressing cells increases the content of MCH class II content on the exosome surface. 69 Another study by Hoshino et al. showed the exosome populations were reduced by Hrs knockdown in head and neck squamous cell carcinoma cells, using NTA analysis. 101 Epithelial cells can secrete exosomes apically and basolaterally to eliminate unfavorable lipid and proteins from entering into the lumen. 102 Another study suggests that inflammation induced by IL-1β can be counteracted by primary bone marrow macrophages-derived exosomes carrying MHC II membrane protein. 103 The study also confirms that MHC II expression is lower in healthy tissue than in inflamed regions. Exosomes will play a vital role in the future of precision and personalized-based medicine against cancer, infectious, rare, and immune diseases.

Recently, exosomes gained much attention for their intrinsic properties such as cell−cell communication, immune response, and antigen presentation across various disease models. 104 Like cells, exosomes are composed of a lipid bilayer that can facilitate loading both hydrophobic and hydrophilic drugs. 57 Exosomes are widely distributed in human blood, serum, urine, and bodily fluid. They typically have low immunogenicity and a longer half-life than many other available drug delivery vehicles. 105 Furthermore, the exosomes have advantages over similar polymeric vehicles due to their inherited surface markers and receptors with its target cells, thus increasing targeted drug delivery to specific tissue/cells. 106 Important points to remember: because of the variation in the size of different cell-secreted vesicles, the exosome's (30−150 nm) related purification and isolation processes are critical. The size of the particle plays a crucial role in targeted drug delivery. It is essential to use around 100−200 nm particles for the exosome delivery method. 104−106 Robust methods of purifying exosomes from cell culture media rely on minimizing copurifying protein aggregates and other membranous particles. Thankfully, different laboratory-based isolation protocols are available, such as differential ultracentrifugation, 107 sizeexclusion chromatography, 108,109 immunoaffinity-based capture, 110,111 exosome precipitation, 112 polymer precipitation, 113 microfluidic-based isolation, 114 and commercially available kits that scientists use to yield exosomes.

When a heterogeneous mixture (suspension) is centrifuged, more abundant and denser particulate constituents in the suspension will precipitate first ( Figure 2 ). Centrifugation is employed to isolate and purify exosomes and enzyme hydrodynamic properties of polymeric particles such as proteins and nucleic acids. 115−117 Depending on the centrifugation force, exosomes can be separated according to their size and viscosity. Ultracentrifugation (UC) is a centrifugation process optimized for high centrifugal forces up to 1000000g. There are two branches of ultracentrifugation: analytical and preparative. 118 Analytical ultracentrifugation is an isolation process depending on particulate material physicochemical properties and molecular interactions of polymeric materials. Preparative ultracentrifugation plays a crucial part since it is used to separate small particles such as viruses, bacteria, subcellular organelles, and exosomes. 49, 111, 118 Ultracentrifugation-based isolation is considered the benchmark and the most studied isolation method in published research. 119 In brief, the culture supernatants were cleared of cell debris, large proteins, dead cells, and large vesicles by sequential centrifugation at 300 g for 10 min (to remove cells), then 1000g for 20 min (to remove apoptotic bodies), and finally, 10000g for 30 min (to remove microvesicles), followed by filtration using either 220 or 450 nm syringe filters. Then, the cleared samples were spun at 100000g for 1−2 h to pellet the exosomes. 120 To avoid contamination by the FBS-derived exosomes, FBS was spun at 100000g for 2 h to remove exosomes before the cell culture experiment. 48, 121 Differential filtration is also applied to separate exosomes from cell culture medium or serum. First, dead-end (normal) filtration uses a 100 nm membrane filter, depleting floating cells and large cell debris. Second, the filtrate undergoes tangential flow filtration via 500 kDa molecular weight cutoff (MWCO) hollow fibers. 122 Then concentrated samples are further filtered using biofiltration. Size-exclusion chromatography (SEC) separation technique is also applied to exosome isolation. In SEC, stationary phase gels like sucrose or Sepharose are utilized to sort differential molecular size.

Samples with small radii will get trapped in the pore opening, letting larger particles go down fast. When this technique is performed using organic solvents, it is called gel permeation chromatography (GPC). 125 The main application of GPC is found in polymer analysis. 125 When size-exclusion chromatography is performed utilizing an aqueous solvents column, the method is called gel filtration. 123 The disadvantages of these methods are (i) the susceptibility of the chromatography column to contamination, (ii) the need to collect and analyze a larger fraction of exosomes to obtain a larger exosome subpopulation, and (iii) the length of time for post exosome isolation. 115 Immunomagnetic isolation uses antibody-labeled magnetic beads and captures exosomes with stained antibodies using a magnetic field. 111 To isolate and purify polymers from other unwanted materials, polymeric precipitation is a technique used to form a mesh-like net structure that embeds exosomes between 60 and 180 nm. Polymeric precipitation isolation methods have advantages in detecting biomarkers of identified exosomes. 113 Several immune isolation assays based on either magnetic beads or microfluidic devices have been able to use antibody-based affinity capture for rapid exosome isolation. 126, 127 These methods depend on the availability of specific exosomal surface proteins or antibodies for discrimination between the exosomes of interest and other vesicles' sizes in the fluids. 126, 128, 129 In Figure 3 , we try to rationalize from a recent study, where authors have compared the ultracentrifugation method with the commercially available isolation kit ExoQuick.

The study confirms how the commercial kit more precisely isolates exosomes. A immunoblot of purified exosomes isolated by ExoQuick shows a wider band than that of the exosomes isolated by UC. Finally, we will mention the commercial kits available for exosome isolation. Some of the prevalent kits typically used such as ExoQuick, Ultra exosome precipitation solution (EXQ) 130 by System Biosciences, total Exosome Isolation for serum or plasma (TEI), 131 exoRNeasy Serum/ Plasma midi kit (EXR), 132 and RIBO exosome isolation reagent (REI) 133 yield relatively pure isolation.

Exosome characterization is very challenging due to the heterogeneity of the exosome population, different isolation techniques, the mixed-size-distribution, and the difficulty in cargo profiling. For exosome characterization, general instrumental methods used for particle size, hydrodynamic diameter, and surface zeta potentials are nanoparticle tracking analysis (NTA) 134 and dynamic light scattering (DLS). 135 For morphology characterization, available techniques are scanning electron microscopy (SEM) 134 and transmission electron microscopy (TEM). 135, 136 Western blot analysis 136, 137 and mass spectrometry 136, 138 have been widely used for biological characterization and proteomics. The electron microscopy technique is the gold standard for characterization of exosome morphology. However, morphology observed by TEM contradicts that of the morphology observed by SEM. TEM images show that exosomes are cup-shaped, whereas SEM images show that they are roughly round shaped. One drawback of the TEM/SEM technique is that the system requires a thin sample; therefore, sample preparation is tedious, affecting exosome properties. The nanoparticle tracking analysis (NTA) technique is another way of determining sizes of exosomes. NTA utilizes Brownian movement of the exosomes to determine the size and particle concentration. 139 DLS is also based on a similar principle where the hydrodynamic radii of the exosome solution determine the fluctuations in reflected laser transmission caused by the Brownian motion of the particles. Different molecular profiling approaches were applied for proteomic analysis of exosomes. In particular, twodimensional gel electrophoresis (2DGE) and liquid chromatography coupled tandem mass spectroscopy (LC-MS) are predominantly used. 140−143 However, compared to proteomic analysis, lipid and metabolite analysis of exosomes is underutilized. The main limitation of proteomics and lipidomics is the risk of contamination of other extracellular vesicles, mainly caused by the isolation techniques. Exosome isolation purification can be determined by Western blotting (WB) or RT-qPCR. Both techniques develop bands from protein or RNA purified from exosomes. Fluorescent imaging is another characterization assay that uses lipophilic dye such as PKH67, Dil, DiD, or DiR embedded in the lipid bilayer of the exosomes. For drug delivery application, characterization assays such as NTA, WB, TEM, and RT-qPCR are enough to demonstrate various physical and composition properties. For biomarker analysis, WB or PCR are used to identify specific protein/metabolite expression in pathogenic exosomes.

This section provided an overview of exosome isolation techniques and characterization methods that are opening a new window toward developing safer and more advanced 

One of the most promising forms of targeted drug delivery revolves around implementing insoluble drug loading in lipidbased systems for enhanced accumulation in the diseased tissues. Exosomes gained much interest in the scientific community of drug delivery because they can carry various molecules, including carbohydrates, proteins, lipids, and nucleic acids. 24 Besides, the exosomes themselves can vary in size from 30 to 150 nm in diameter, depending on the type. This variability in the potential transport vehicles creates opportunities for the loading and targeting of a diverse array of biomolecules to provide therapy to targeted organs in the body 144 ( Figure 4) . A reliable means to load small hydrophobic molecules has been found using sonication, which works by causing shear forces in the exosome that allow drug molecules to accumulate in the lipid layer of its membrane. 145 Effective methodologies have utilized a direct probe and a set, consisting of 30 s of sonication and 30 s of rest, repeated six times. 145 This method was used to load macrophages with paclitaxel (PTX), a potent chemotherapeutic agent and an eminently hydrophobic compound. The study showed the most significant relative particle size (287.7 ± 0.7 nm) that displayed the highest encapsulation efficiency (EE) (28.29 ± 1.38%). This method's efficiency was significantly higher than other loading methods of the same drug, including electroporation or incubation, with neither reaching above 6% EE. 145 Similarly, the catalase for Parkinson's study used an almost identical method, producing only moderate sizes (179.0 ± 10.6 nm unloaded, 183.7 ± 13.8 nm exoCAT loaded) but also received the highest relative loading capacity (<200 μg catalase/mg exosome). The nature of this loading method allows for drug fusion to the membrane, which may inhibit total controlled release due to an initial burst phase. Incubation has been attempted in the previous study, which involved shaking for 1 h at 37°C. This resulted in a significantly smaller particle (132.2 ± 2.3 nm) with a spare loading capacity (1.44 ± 0.38%). 48 In the same article, the authors had showed that the catalase in the Parkinson's study was added to 250 μL of exosomes for a final concentration of 0.1 mg/mL complete protein. Before the addition of catalase, the macrophages were diluted in PBS (0.15 mg/mL total protein). The sample was then incubated at room temperature for 18 h. Sizing was 108 ± 14.3 nm, and loading was measured by enzymatic activity, which was rated very low (>20 μg catalase/mg exosome). A side note is that postloading sizes of incubated exosomes were relatively similar; however, this may be due to this method's deficient efficacy level. SEM images show that this method creates abnormal nonspherical shapes, which may have unintended effects in a therapeutic context. The freeze−thaw loading cycle was attempted in the catalase for Parkinson's study, which involved adding the exosomes and catalase identically to the incubation loading, allowing them to incubate for 30 min, then to freeze at −80°C rapidly, and then to thaw at room temperature (RT). This cycle was repeated three times and was somewhat successful, with an average size of 147.0 ± 10.0 nm unloaded, 158.0 ± 11.0 nm loaded, and ∼100 μg of catalase/mg of exosome. Continuous freeze−thaw cycles have been shown to cause fluctuations in fluorescence due to lipid-dilution ratio changes. Extrusion is performed by placing the catalase mixture in an Avanti lipids extruder with 200 nm pore diameter and then purifying it using gel-filtration chromatography with Sepharose 6 BCL. Sizing was consistent and small (134.0 ± 7.5 nm unloaded, 154.8 ± 11.0 nm loaded), and loading (190−200 μg catalase/mg exosome) was the second most effective drug-loading method after sonication. 48 Morphology data show a spherical and consistent shape. Electroporation was attempted in the PTX study with abysmal results. The exosomes and PTX were added to a chilled 4 mm electroporation cuvette, subsequently electroporated using an Eppendorf evaporator at 1000 kV for 5 ms, and then incubated at 37°C for 30 min to allow for the recovery of the exosomal membrane. 147 This method resulted in an average size of 145.3 ± 1.0 nm, but encapsulation was low (5.3 ± 0.48%). In brief, exosomes could be loaded with drugs either in vitro in purified exosomes or in vivo during biogenesis ( Figure 4 ). Transfection is a technique for loading proteins, peptides, and nucleic acids into exosomes. Using specific transfecting agents such as plasmids or tethers, the cell can be transduced to ectopically express desired proteins, lipids, or nucleic acids which will later undergo exocytosis from the cell via exosomes. For example, Bellavia et al. transduced human embryonic kidney 293 (HEK293) cells using BCR-ABL siRNA and later collected exosomes from cell medium. 148 Yang et al. has also shown that different transfecting cells with mRNA can produce a 50-fold higher exosome amount compared to the naive cell culture technique. These exosomes carrying PTEN mRNA restore tumor-suppression function in the brain, increase animal survival, and enhance tumor-growth inhibition. 149 Except for nucleic acids, we can introduce specific proteins or lipids via transfection techniques. For example, HEK293 cells were transfected with CD9-human antigen R (HuR) to facilitate the loading of miR-155 into exosomes. 150 Another study showed that HEK293 cells transfected with vascular stomatitis virus glycoprotein (VSVG) enabled exosomes to penetrate the plasma membrane of recipient cells. 151 Further, exosome cargo can also modulate by expressing cargo-sorting proteins onto exosome surfaces via cell transfection. This cargo loading technique is promising; yet, its cargo loading efficiency is low due to cargo selectivity and chemical impurity due to transfection.

Electroporation is another technique for loading DNA, mRNA, siRNA, and RNAi into exosomes. In this technique, the electric field is applied to increase permeability for small molecule drugs and large molecule biologics through the membrane of exosomes. For drug loading, the exosome and payload (drug/protein) need resuspension in an electroporation buffer. The electroporation buffer can be trehalose pulse medium (TPM; 50 mM trehalose (Sigma-Aldrich, Cat. No. T0167) in PBS) or (1.15 mM potassium phosphate, pH = 7.2, 25 mM potassium chloride, 21% Optiprep) or cytomix electroporation buffer (120 mM KCl, 0.15 mM CaCl 2 , 10 mM KPO 4 , 25 mM HEPES, 2 mM EGTA, and 5 mM MgCl2, adjusted to pH 7.6 with KOH). 152, 153 Then electroporation is carried out using a GenePulser Xcell electroporator (e.g., from Bio-Rad). All samples are filtered using omega membrane Nanosep centrifugal devices (100−3000 MWCO, depending on the size of payload) to remove the excess payload of drug, DNA, or mRNA. Measuring the volume of samples being loaded into the electroporation buffer is also important. Depending on the loading protein, the voltages and capacitances of the electroporator will differ. 154 Some studies report that electroporation leads to exosome aggregation, resulting in a lower loading efficiency. That is why it is recommended to filter the electroporated sample with a 450/ 220 μL filter.

Surfactant treatment is another technique for exosome drug loading. Surfactants such as saponin or triton are used to increase the membrane permeability of the exosome through simple incubation methods. 155, 57 Incubation with surfactant can be used to facilitate the loading of the antioxidant and catalase into exosomes, and provide neuroprotective efficiency of post-intranasal administration in a Parkinson's disease (PD) animal model. 48 Although the surfactant enhances higher loading efficiency within the exosome, some limitations exist in the technique. Surfactants may inactivate/degrade the potential function of therapeutic or loading cargo, and excessive surfactant may cause in vivo hemolysis. Additional purification methods may need to be implemented after incubating with the surfactant. 155 Hypotonic dialysis is another drug-loading method widely used for exosome drug loading. The basic principle is that an exosome and drug mixture is placed in a dialysis tube and continuously stirred to allow for drug loading. This method can load 11-fold higher drug content than a room temperature incubation loading method. 156 This loading system is also suitable for reducing intra-exosomal pH by rehydrating and dehydrating the exosome in acidic citrate and ethanol buffer. This pH gradient of exosome helps to load miRNA and siRNA. 157 Some studies report that the dialysis loading method may induce protein degradation due to the pH change of the exosomes. 158 Therefore, this method is considered as a highly effective drug-loading method; yet, proper validation is needed to identify the experimental conditions and exosomal cargo selection.

Today, numerous drug-loading techniques have been developed in light of the exosome's intrinsic properties for drug loading and delivery (see Figure 4 and discussion earlier in this section for details). In incubation methods, drug-loading efficiency depends on the proportion of drug and exosome protein concentration. The loading efficiency of incubation methods is poor, and certain factors influence efficiency. First, in gradient-based cargo diffusion, the concentration of cargo is curved due to the saturated concentration of the drug, indicating the enhanced drug-loading profile. Second, the membrane integrity of the exosome restricts most of the hydrophilic drug to the influx. To increase the loading efficiency, we need physical triggering methods such as sonication, extrusion, electroporation, surfactant treatment, dialysis, etc. Multiple studies conducted in parallel demonstrate that drug-loading efficiency increased with these physical treatment methods compared to the general incubation methods. 48, 159 Despite higher drug-loading efficiency, the physical methods have many disadvantages for drug delivery application of exosomes. First, surfactant treatment may introduce impurities in the exosome, which may cause toxicity during therapy. Second, electroporation may destabilize the exosome membrane integrity or cause severe aggregation. Third, dialysis treatment may cause the inactivation or degradation of the protein loaded. Fourth, the ultracentrifugation method provides us with a mixture of extracellular vesicles, e.g., ranging from 30 to 150, which is satisfactory for biomarker analysis but not for drug delivery where we need a precise range of particles. Fifth, the freeze−thaw method, due to multiple freezing and thawing cycles, can cause degradation of the exosome membrane and a leaky structure. Transfection is another way to increase the loading efficiency of protein, lipids, and nucleic acid via transducing cells or exosomes with nucleic acids or proteins expressed by a plasmid. However, this technique is costly and time-consuming, making it unstable for small-scale research purposes. Overall, exosome loading techniques can improve desirable cargo but introduce impurities that affect exosomal properties. Therefore, we need to use particular loading techniques depending on the exosome application and consider the implications of the introduced impurities for drug loading. The purification of exosomes is laborious due to their intrinsic biological properties, making them more difficult to use for drug loading. Engineered exosomes provide an alternative means to overcome drug-loading issues. If we can develop or utilize current techniques such as plasmid, tether, or bio-ortholog click chemistry, we can generate the desired exosomes from cell culture. In this way, we can avoid drug-loading steps and have stabilized exosome treatment that can be used to combat cancer, immune, and rare diseases. We can also consider how to remove natural exosomal cargo during exocytosis, allowing us to load more therapeutic payload during the drug-loading step. However, the optimization of exosome loading strategies is limited by our insufficient understanding of exosome biology, structure, biogenesis, and lagging exosome-related research and development tools. 60 We need a standardized drug-loading protocol for getting uniform and stable results in drug delivery applications both in preclinical and clinical studies.

5.1. Role of Exosomes in the Immune System. Exosomes play an important role in immune regulation, eliciting both positive and negative "unwanted" immune responses, including tolerance and evasion. 160−162 Individually, exosomes can act as immunoregulating agents by modulating immune activation, antigen presentation, suppression, and surveillance. 163−166 The exact mechanisms for many of these actions are not entirely understood. Several studies have begun to reveal how these vesicles play necessary and frequently pivotal roles in initiating various immune responses. 167−169 The inflammatory response is often signaled by exosomes, meaning that these vesicles play a crucial role in several pathological states, including cancer, diabetes, obesity, and neurodegenerative disease. 28,170−174 For example, microRNAs regulate cell gene expression after transcribing, and exosomes deliver microRNAs to recipient cells. A study by Alexander et al. shows dendritic cell-derived exosomes delivering miR-155 and miR-146α to recipient dendritic cells to promote endotoxin-induced inflammation in mice. 171 In neurodegenerative Alzheimer's disease, exosomes carry pathological misfolded proteins to neighboring neurons, thus promoting a cascade of exosomes carrying pathological misfolded proteins to other neighboring neurons, initiating disease onset and propagation. 175 The study of exosome cargo release may lead to the identification of biomarkers for many of these diseases. Since exosome cargo is a continuously excreted substance via fluids, saliva or urine collection may be valuable pathological screening tools for biomarker identification. 176 We will discuss exosome biomarker applications in more detail in section 5.4 of this review. Exosomes also play an essential part in cardiovascular disease recovery by promoting tissue repair and regeneration. 177, 178 Exosomes originating from immune cells play a significant role in prompt immune response and ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review inflammation, unlike stem cells and cardiomyocytes. 179 Although these mechanisms are not well studied and only a small number of exosomes directly related to immune response regulation have been discovered, what is known is that exosomes demonstrate cardioprotective effects against postinfarction and atherosclerosis. One example of exosome-based manipulations may found in a study published in Allergy, 180 where B cell-derived exosomes with pMHC II found on FDCs could stimulate CD4+ T-cells, which aided their development.

Scientists believe that pMHC II found on the FDCs likely allowed the exosomes to engage the T-lymphocytes, modulating immune memory to expand their collection of antigens. Activation of the immune system may also be triggered by exosome activity. 181 Dendritic cell (DC) exosomes classified as "mature" are significantly more effective than their younger counterparts when inducing specific antigen T-cell activation. 181 This phenomenon is most likely due to distinct differences in protein composition that accumulate as the cell matures. 181 These changes can help in tumor suppression; however, these same effects have occasionally been hijacked by tumor cells, allowing for uncontrolled growth without a proper response. Recently, a study found that tumor cells can bypass the typical immune response by upregulating the surface expression of programmed death-ligand 1 (PD-L1), allowing the tumor to mask itself by eliciting the immune checkpoint response. 120 Effective quantification of PD-L1 could be used as a possible tool for helping in tumor treatment decisions based on the amount observed at specific sites. 182 This line of investigation closely follows the migration and composition of these vesicles. Peptide transfer acting as a form of cell-to-cell communication via exosome migration can have profound biological effects. 183 For example, prion proteins from the exosome walls may be transferred to uninfected cells by fusing with their uninfected counterparts. 184 In pregnant women, placenta-derived exosomes circulate T-cell activating markers including Fas ligands and HLA-DR. These exosomes also show greater suppression of JAK3 and CD3-zeta (T-cell coreceptor) than prepregnant circulating placenta exosomes. 185 Dendritic and lymphoid cell-derived exosomes regulate immune activation. Tumor-derived exosomes (TEX) have also been considered as a vaccine platform due to their effects on T-lymphocytes, suppression CD3-zeta, and JAK3 expression. Thus, TEX expressing tumor antigens can suppress T-cell signaling and induce apoptosis for potential use as a tumor vaccine. 186 In another study, the authors compare the molecular profile of TEX with healthy controls circulating Figure 5 . Recent studies confirm that exosomes can pass through the blood−brain barrier (BBB) 201−204 in both directions. This means that specific exosomes detected in the cerebrospinal fluid (CSF) or in the blood from the brain can be released into the bloodstream and vice versa. Each cell type releases a specific type of exosome(s) that is released and communicates with neighboring cells, acting as the messenger. This characteristic makes exosomes attractive as new sources of biomarkers and therapeutic targets suitable for use in clinical practice, such as a liquid biopsy that could replace current invasive diagnostic methods. Exosomes also have a potential role in drug delivery for brain disease models, and their membrane markers can be used to identify their cellular origin.

exosomes. They found that TEX downregulates both CD3-zeta and JAK3 expression of activated T-cells and Fas/FasLdependent apoptosis. TEX were incubated with activated Tcells, CD56(+) CD16(+) NK (natural killer) cells or conventional CD4(+) CD25(neg) T-cells res. Also, the authors showed how TEX promotes CD4(+) CD25(neg) Tcell proliferation but suppresses it when they transform into CD4(+) CD25(hi)FOXP3+ (FOXP3 is forkhead box P3) Treg cells (regulatory T-cells). Therefore, TEX has immunosuppressive properties that depend on the T-cell activation state. 187 Tumor cells escape the immune checkpoint by upregulating PD-L1, which interacts with the program death-1 (PD-1) T-cell receptor. 188, 189 Anti-PD-1 or anti-PD-L1 antibodies have shown promising results in treating tumors. 190 Along the same lines, metastatic melanomas releasing exosomes containing PD-L1 can suppress CD8 T-cells, preventing proliferating tumor growth via IFN-ϒ stimulation. 183 This study unveiled a mechanism for how tumor cells suppress the immune system initially and how exosome PD-L1 is a potential target for anti-PD-1 therapy. In autoimmune diseases studies, T-cell regulation is a key mediator of diseases treatment, and some of the mechanisms are suppressed by Treg cells, apoptosis of overactivated T-cells by cytokines destitution, immune checkpoints such as PD-1, and CTLA-4 expression. 191, 192 Multiple previously published reviews and research articles conclude that exosomes released from immune cells play both preventive and developmental roles in autoimmune diseases. 193, 194 Mesenchymal stromal cell (MSC) exosomal immune properties are well studied. Zhang et al. showed that MSC-derived exosomes induced production of CD4 + CD25 + Foxp3 + Treg or CD4 + CD25 + T-cells via allogeneic APC-enriched CD11C + cells through T-cell activation. 195 This activation is both exosome and APC dependent.

Exosomes' intrinsic properties of cell-to-cell communication allow for the transfer of potentially toxic proteins without the need for direct contact. However, this type of communication may also be used in a manner beneficial to the immune system by allowing for a more robust and adaptable transfer of antigenic markers between cells, which would bypass the need for a more abrasive communication route. Overall, understanding of the role that exosomes play in the immune system response is still in its infancy. A great deal of research must be done to gain insight into the complex interactions that elicit the varied responses discovered. This field's foundation will need to focus on mechanistic and response-oriented inquiry to understand how these vesicles can be fully utilized.

5.2. Role of Exosomes in Blood−Brain Barrier (BBB) Penetration. The BBB is a protective mechanism that helps maintain a stable chemical environment in the brain. 196, 197 No other body organ or tissue is as protective and dependent on maintaining the internal environment as the brain. 196 For blood and proteins to reach the brain through brain capillaries, these products must cross three barriers, (i) the endothelium of the capillary wall, (ii) external capillaries of the wall covered by relatively thick basal lamina, and (iii) the bulbous "feet" of the astrocytes clinging to the capillaries ( Figure 5 ). Nutrients such as glucose, electrolytes, and essential amino acids can penetrate the BBB via passive diffusion through the endothelium cell membrane. 198−200 On the contrary, small nonessential amino acids and potassium ions are prevented from entering the brain. They are actively pumped out from the brain through endothelium capillary action. 198 Transport across the BBB is catalyzed by transport processes such as carrier-mediated/receptor-mediated transport, and active efflux transport. 205−207 Efflux transport protects the brain from ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review endogenous substances such as neurotransmitters and hormones and is also vital for drug transportation to a diseased brain region. 208 At places of high glutamate presence in the diseased brain, the brain's glutamate levels are regulated by the BBB through the use of excitatory amino acid transporters (EAATs 1−4). 205 Because of the limited ability of most drug delivery methods, an alternate approach is required. Thus, exosomes may work as a cloak, which can have elevated drug-loading amounts and better-targeted delivery. 48 Recent advances in exosome research regarding their intercellular communication and their organotrophic behavior opened a new door in targeted drug delivery research. 209, 210 For cell−cell communication, the surface of the exosome is enriched with cell-adhesion targeting molecules (tetraspanin and integrin), antigen-presenting molecules (MHC I and II), membrane trafficking molecules, and receptor proteins. 211 For example, tetraspanin proteins CD9, CD63, and CD81, isolated from brain endothelial HCMEC/D3 cells, play a crucial role in communication between primary astrocytes and cortical neurons. 201 Exosomes derived from neuronal glioblastoma (GBM) and neuroectodermal cells cannot cross the BBB, whereas exosomes derived from endothelium cells that have a tetraspanin marker as CD63 can. 212 Also, endothelium cell exosomes can pass through the BBB using cell-specific proteins via receptor-mediated endocytosis. 212 Hypoxic GBM U87 cells release exosomes through VEGF-A induced BBB permeability for tumor invasion, endangering brain health integrity. Authors found GBM exosomes alter/reduce the expression of claudin-5 and promote BMVECs. 204 In zebrafish, exosome-loaded doxorubicin, and paclitaxel, show promising ability to cross the BBB, whereas neither of the drugs showed brain uptake by themselves. 201 In Figure 6 , 213 the authors show that the CSF can carry exosomes and constituents, observed by TEM imaging. Interestingly, NTA analysis confirms an exosome population increase in CSF due to systemic LPS injection compared to control CSF. This experiment validates our conclusion that the exosome number increases due to the disease state. miRNA analysis also confirms that exosomes can carry payloads such as miRNA and mRNA proteins. These data validate the exosome's capability of drug delivery of active biologics to the brain in a disease condition. In HIV patients, the role of amyloid beta (Aβ) deposition is one of the characteristics, and the BBB plays a critical role in Aβ homeostasis within the brain. It was reported that HIV-1 infection increases exosome release from brain endothelial cells and higher Aβ cargo in the brain compared to a healthy control. 214 This study concludes that exosomes carried cargo across the BBB and successfully delivered it to the brain. Aβ plaques accumulation is also a pathological characterization of Alzheimer's disease. 215 The review by Badhwar et al. summarized how blood exosomes could be a potential source of biomarkers for Alzheimer's disease. The authors compiled about 26 previously published studies on blood exosome biomarkers and other sources such as neuron, astrocyte, and brain vasculature exosomes biomarker screening. This study provides a correlation of blood exosomes with exosomes derived from other brain fluid sources. 216 Parkinson's disease (PD) is another deadly brain disease and a common movement disorder. Dopamine administration is one of the main treatments used for PD. Qu et al. have reported that dopamine loaded in blood exosomes showed and improved therapeutic results in the PD mouse model and reduced systemic toxicity compared to free dopamine administration.

Blood exosome (40−200 nm) shows a promising targeted drug delivery approach for PD treatment. 217 In Figure 7 , the study shows that the authors investigated the correlation of miRNA expression due to peripheral inflammation in the brain region. The authors also found systemic TNF injection increases the total amount of exosomes released and found a significant increase in the expression of miR146a and miR155 due to LPS injection in vivo. 213 From the above discussion, we found that exosomes can cross the BBB and carry payloads back and forth from the inner and outer lumens. Thus, exosomes provide another avenue for therapeutic drug delivery to fight against brain diseases and brain-related cancers that are untreatable with current therapeutic agents. 212, 217 5.3. Role of Exosomes as a Drug Delivery Vehicle. Currently, the most preferred drug delivery systems are based on biodegradable liposomes or biological exosomes. Because of novel developments through exosomal research, several exosome-based drug formulations are currently in clinical trials, and recently some have been approved for clinical use. 218 Exosome bilayer-based drug delivery benefits the payload alternation of its biodistribution and higher encapsulation capacity. 218 Biological exosomes are also commonly used as drug delivery vehicles because of their overall bioavailability, improved drug encapsulation coupled with a controlled release, longer circulation time, and lessened toxicity. 219−221 Biodegradable nanoparticles like exosomes have successfully encapsulated bioactive molecules such as curcumin, 222 paclitaxel, 223 neurotoxin-I, 224 and dexamethasone, 225 all of which improve biodistribution and controlled release. Additionally, biodegradable nanoparticles are also utilized as drug delivery vesicles for multiple disease models of cancers, 226, 227 diabetes, 228 and brain diseases such as Alzheimer's, 229 prions, 230 and Parkinson. 48 Most of these medications have translated into clinical trials, and some have already been introduced to the American market. 231 On the other hand, liposomes, PLGA, PLA, or poly(lacticco-glycolic acid) are the most common and well-studied nanoparticles (NPs) for targeted drug delivery applications. 232−235 Many liposomal and PLGA NPs mediated formulations have been successfully translated to the clinic and have obtained FDA approval: Doxil (liposomal doxorubicin), 236 DaunoXome (liposomal daunorubicin), 237 Onivyde (liposomal nanoformulations of irinotecan), 238 Cimzia (a PEGylated blocker of tumor necrosis factor-alpha (TNFα)), 239 Neulasta (PEGylated form of filgrastim), 240 Vivitrol (PLGA L/G 75:25 with active ingredient naltrexone), 241, 242 and Signifor LAR (PLGA with active ingredient pasireotide pamoate, treatment for acromegaly). 243, 244 One of the main challenges in translating polymer-based formulation is the behavioral difference between in vivo models compared to in vitro. To overcome the existing challenges in biocompatibility, diffusion, cell internalization, and tissue transportation, further studies are needed to thoroughly investigate utilizing different animal models. 245 These biodegradable polymeric vehicles accumulate in the reticuloendothelial system (RES), including the liver, spleen, kidney, lymph nodes, and bone marrow. Polymeric NPs are cleared by resident APCs, like macrophages, via direct interaction and increase immunosuppression and risk of infection. 232, 246, 247 Plasma proteins also play a pivotal role in clearing polymer-based drug formulations from the RES via opsonization. 248, 249 Liposome and PLGA NPs also interact with immune cells in the blood and resulting in ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review antibody production against NPs different functional components due to repeated injection. 45,250−252 This phenomenon is called the "accelerate blood clearance (ABC)" phenomenon. Dams et al. first observed the ABC phenomenon that when animal models were administered with empty PEGylated liposomes, it influenced biodistribution and pharmacokinetic behavior of the second dose of PEGylated liposomes after 7 days. 253 Some polymeric NPs also induce an innate immune response due to subsequent activation of the complementary system known as complement activation-related pseudoallergy (CARPA). 254 CARPA has been observed from clinically approved liposome formulations (e.g., DaunoXome and Doxil). 255 Another challenge, specifically for tumor-targeting polymeric NPs, arises from the complexity and heterogeneity of the tumor's microenvironment, resulting in the accumulation of NPs in neighboring healthy cells. 256, 257 Lastly, polymeric and biodegradable nanoparticle delivery systems' development and marketability, even with their ability to evade the host immune system with extended circulation, stability, and low toxicity, have remained elusive. 258 To overcome the limitations of most biodegradable/ polymeric nanoparticles, 259 exosome-mediated drug delivery 210 provides superior features including long circulation halflife, 260 enhanced cell-specific targeted delivery, 145 increased biocompatibility, 104,261 reduced/low toxicity, 262,263 ability to stimulate an immune response against pathogens, 161 antitumor modulation, 161 antigen presentation, 264 etc. Exosomes have been utilized as a drug delivery vesicle in multiple studies using low-molecular-weight drugs, active biologics (lipids, nucleic acids, siRNA, proteins), and larger antibodies. 41,201,265−269 For example, the exosome-mediated delivery systems using curcumin have already shown great potential over conventional drug delivery systems. 270 Curcumin, an antioxidant that has chemotherapeutic properties, is a natural polyphenol found in the rhizomes of turmeric. 271−273 Alvarez-Erviti et al. reported expressing a neuron targeting a protein on the exosome surface with postloading using siRNA, followed by injection into the mouse bloodstream. The authors have achieved specific gene knockdown in the brain and proof of the exosomal capability of crossing the BBB without inducing any immune response. 268 Another ongoing challenge in delivery science is targeting the subcellular compartment of specific cells. For instance, targeting nuclease and delivering the CRISPR-Cas9 system are very attractive to the scientific world and have a higher precision for gene editing. Scientists can deliver large plasmids, including the CRISPR-Cas9 expression vectors loaded in exosome, to mesenchymal stem cells. 269 This study validates that exosomes can deliver cargo to recipient cells and gives insight into in vivo gene editing potentials against multiple diseases. 269 Delivery of antibodies and active biologics is also a promising platform in the drug delivery field. Wan et al. has reported on the modification of aptamer-based DNA on exosomal surfaces by DNA hybridization chain reaction, enhancing exosome functionality and showing potential for broader biomedical applications such as targeted drug delivery, cell-free therapy, and gene knockdown. 41 Acquired drug resistance is a challenging mechanism against cancer chemotherapeutics, and it has been reported that exosomes play a critical role in this drug-resistance transfer among cancer cells. Lv et al. has shown that drug-sensitive MCF-7 cells (MCF-7/s) become drug resistant after treatment with exosome isolates from the docetaxel-resistant variant MCF-7 cell line (MCF-7/ DOC). 274 The authors also found that P-glycoprotein (P-GP) expression is higher in exosomes from MCF-7/s cells after treatment with MCF-7/doc exosomes, indicating P-GP has a role in drug-resistance transfer among the cells. In 1996, Raposo et al. first observed the role that exosomes play in adaptive immune system stimulation via antigen presentation. 275 Exosomes also carried and presented MHC I/II to modulate the antigen-specific CD8 + and CD4 + via direct and cross-presentation. 276 Bianco et al. showed that immature dendritic cell-derived exosomes inhibit inflammation in a murine footpad model via inflammatory cytokines IL-10 and IL-4. 277 Another study by Chen et al. showed mesenchymal stem cell-derived (MSC) exosomes increased the concentration of anti-inflammatory factor TGF-β and suppressed the secretion of pro-inflammatory factor IL-1β and TNF-α. 278 Besides, MSC exosomes also induced the transition of Th1 to Th2 cells and reduced the potential to differentiate into interleukin 17-producing effector T-cells (Th17). Thus, MSC exosomes have the intrinsic properties of modulating the tumor microenvironment's immune response and providing immune protection via exosomes. T-and B-cell-derived exosomes also play a vital role in immune modulation. For example, mouse B-lymphoma cell-derived exosomes carry heat shock protein 70, modulating the antitumor immune response in T-cells. 279 In another study, dendritic cell-derived exosomes primed with acid-eluted tumor peptides eradicated tumors in mice. 280 Exosomes from T-cells also improved the immune response with the help of communication with endothelium cells by destroying tumor stroma and preventing tumor metastasis. 281 Immune modulation is achieved by bioactive lipids and proteins of the exosome and exosome mRNA. Aucher et al. reported that human macrophage exosomes functionally inhibit cancer cells proliferation by delivering miRNAs to hepatocarcinoma cells (HCCs). 282 Another study based on MSC-derived exosomes showed that the paclitaxelloaded exosome inhibits in vitro tumor growth. 283 The study by Pascucci et al. showed the effect of murine MSC SR4987 line exosomes loaded with paclitaxel (PTX) and delivered to the human pancreatic cell line CFPAC-1, which possessed intense antiproliferation activity against CFPAC-1. 283 PTXloaded MSC exosomes showed higher cell target specificity as well. Rani et al. also reported that MSC-derived exosomes play a crucial role in its paracrine function. 266 Another study by Kalimuthu et al. showed paclitaxel (PTX) loaded with MSCderived exosomes could accelerate anticancer treatment against breast cancer (MDA-MB-231) cells observed both in vitro and in vivo. 265 Exosomes have been extensively studied for brain drug delivery to improve brain disease and inflammation treatment. A study by Yan et al. has shown that exosomes derived from mouse brain endothelial cell line (bEND3) loaded with doxorubicin significantly reduced growth and proliferation of U-87 MG cancer cells compared to embryos treated with buffer control or drug only. Chemotherapy is the standard and most effective method for cancer treatment, and the above discussion validates that exosome-chemotherapeutic drug delivery reduces side effects through a targeted drug delivery strategy which reduces the overall drug dose needed for the treatment. 284 Zhuang et al. demonstrated that exosomes encapsulated with curcumin (Exocur) and STAT3 inhibitor JSI124 (Exo-JSI124) via LPS induced brain inflammation via microglia cells in a mouse model. The authors have reported the delivery method of Exocur and Exo-JSI124 induced apoptosis of microglial cells. 285 Additionally, exosome-mediated drug delivery systems have been utilized for curcumin delivery, which forms a complex with curcumin that enhances both loading efficiency and the safe transportation for patients in clinical trials. 286 Other great applications of exosomes involve their immune-protective and regenerative effects. MSCs are derived from multiple sources such as bone marrow, adipose tissue, cord blood, and other sources and are getting much attention as potential candidates for regenerative medicine. 287−289 Cardiosphere-derived cells (CDCs) derived exosomes produce a range of cardioprotective measures such as antioxidant, antifibrotic, antiapoptotic, and anti-inflammatory effects. 290, 291 Another highlight of exosomes research is delivery of siRNA. 292, 293 For example, Shtam et al. demonstrated that HeLa cell-derived exosomes delivering siRNA for RAD51 and RAD52 activate apoptosis of recipient cancer cells. 294 Wahlgren et al. also showed that peripheral blood exosome-mediated siRNA delivery efficiently silences the target MAPK gene in lymphocytes and monocytes. 295 Another interesting finding is that analysis of protein and mRNA confirms exosomal-mediated siRNA delivery, targeting successful knockdown of BACE1, a therapeutic target of Alzheimer's disease. 296 Also, a recent study by Haney et al. reported that catalase loaded into exosomes can cross the BBB, improving the disease outcomes in a Parkinson's mouse model. 48 Recent studies have also found that the targeted delivery of streptavidin-FasL (SA-FasL) via exosomes could substantially enhance the therapeutic effects of the SA-FasL protein while minimizing its potential off-target effects often caused by its solubility when doses are delivered by injection. 297 Regarding exosome-mediated vaccine development and delivery, Li et al. reported that the exosomes can transfer TNF-ϒ and induce antiviral activity. 298 Exosomes derived from DCs also show promising potential for targeted immune responses against tumor cells and increased the therapeutic effect compared with cell and noncell based therapeutic strategies. 299 Specifically, mature and activated DC-derived exosomes carry MHC I and MHC II molecules and costimulatory molecules such as CD40, CD80, and CD86 and deliver cargo to active cytotoxic T-and natural killer (NK) cells in vitro and in vivo via potent antigen-specific T-and Bcell responses. 300, 301 Genetically engineered autologous or allogeneic T-cells expressing chimeric antigen receptors (CARs) or T-cell receptors (TCRs) as cellular immunotherapy may also be considered as a promising cancer treatment method. 302 Lu et al. recently reported that exosomes from hepatocellular carcinoma (HCC) antigen-modified DCs could be used as cell-free vaccines for HCC and opens the window for HCC immunotherapy. 303 Another study by Geis-Asteggiante et al. demonstrated myeloid-derived suppressor cells (MDSC) derived exosomes using protein mRNA and miRNA, can induce immune suppression function. 304 Di Bonito et al. used an engineered exosome with the E7 protein of human papilloma virus (HPV). The E7 protein elicited a strong and effective antigen-specific cytotoxic T-lymphocyte (CTL) immunity. 305 A DNA vector expressing HPV-E7 and fused at the C-terminus of an exosome-anchoring protein named Nef mut was injected into mice. 306 In this study, the authors provide evidence that injection of Nef mut /E7 DNA induces similar antigen-specific cytotoxic T-lymphocytes like mice implanted with TC-1 tumor cells. Integrin αvβ6 can convert the latent transforming growth factor (TGF)-β to promote the development of Treg cells. 307 The authors demonstrated that the delivery of cardiovascular exosomes carrying integrin αvβ6 promotes the generation of the donor antigen-specific immune tolerance. On the same line, another study showed DC-mediated exosomes promote heart allograft survival. 308 The authors have finally demonstrated that donorderived peripheral exosomes carrying MMP1a promoted allograft heart survival via inducing donor antigen-specific Treg to attenuate the T helper (Th)2 pattern inflammation. 309 Exosomes offer enormous promise as a contemporary yet promising area for small and large biological molecules' therapeutic drug delivery. As a drug delivery vehicle, exosomes provide an added advantage over polymeric vehicles due to the lack of accumulation of exosomes in the RES, especially the liver, which helps them avoid first-pass metabolic effects before reaching target sites. 297 It is also essential to note that exosome-mediated drug delivery offers a comparatively longer circulation half-life, induces a robust immune response against pathogens, and facilitates subcellular-specific targeted delivery of therapeutics (e.g., to mitochondria and nucleus). 15 However, there is a need for additional investigations into how exosomes react to the body's immune responses before these therapies are accepted as permanent therapeutic methods. 27 This section demonstrates the exosome's robust immune response, drug delivery capacity to any specific target, and carrying of extensive biologics and antibodies, and discusses how scientists can utilize the exosome platform for designing an adjuvant vaccine and therapeutic delivery. Surface modification and engineered exosomes added a plethora of applications for drug delivery, disease diagnosis, and facilitate immunotherapy. Nevertheless, significant effort is required to develop exosome as a personalized therapeutic modality based on patient disease history.

5.4. Exosome as a Disease Biomarker. The National Institutes of Health Biomarkers Definitions Working Group in 1998 defined a biomarker as a quantifiable measure of a normal biological process, pathological process, or pharmacological response to a therapeutic administration. 310 Currently, both invasive and noninvasive methods are employed for biomarker identification. For example, serum analysis of blood samples from cancer patients is well established for monitoring the location and stage of cancer. Exosomes reignite the field of biomarker study. Naturally, the question arises, why do exosomes have advantages in biomarker screening applications? First, MHC-expressing exosomes have the ability of antigen presentation via both direct and indirect pathways. 127, 311 Second, exosomes contain cell-specific surface markers that carry protein and RNA cargo, and are highly stable in storage conditions. 312, 313 The exosome was initially considered an unnecessary protein excreted from cells. However, recent studies confirm the importance of exosomes in cell−cell communication by transporting microRNA, mRNA, and proteins. The membrane bilayer and luminal content of exosomes are protected from extracellular proteases. Multiple exosome sources contribute to the biomarker study; they are urine, saliva, cerebrospinal fluid, blood, body fluid, amniotic fluid, ascites, and cells used to identify and validate biomarker screening. Exosomes contain a variety of lipids, nucleic acids, mRNA, proteins of cytosolic, cell signaling, and membrane trafficking, reflecting the cell type and condition. In a PubMed search conducted on January 20, 2021, 4767 papers were generated related to exosomes and biomarker studies. As a biomarker, exosomes are getting more attention from various groups of scientists as more evidence is emerging that exosomes contain protein and nucleic acids associated with cancer, liver, kidney, neurodegenerative, infectious, and metabolic diseases. Exosomes are easy to analyze and can be stored at −80°C for 1 week to 1−2 years (depending on the exosome source) for future use. 314 More information on exosome biomarkers can be found at http://www.exocarta.org (ExoCarta, a web-based compendium of exosomal cargo) and http://exrna.org (extracellular RNA communication program). Biomarker screening studies utilize multiple tools to analyze specific markers relevant to the disease model. Protein, mRNA, and microRNA content of exosomes are used as a diagnostic tool for biomarker analysis. Most general approaches are flow cytometry (FACS), immunohistochemistry, biochemical analysis (microarray studies, RT-qPCR, Western blotting), surface resonance Raman spectroscopy (SERS), and principal component analysis (PCA). These assays are based on the type of exosome source and disease-specific biomarker.

Proteins found in exosomes from both healthy and disease states are diverse and resemble various disease conditions related to cancer, liver, renal, kidney, and brain diseases. Several proteins have been identified as a diagnostic marker for exosomes. Scaffolding membrane proteins Tetraspanin are enriched on the exosome surface. The study shows plasma CD63+ expression elevated in patients with melanoma compared with a healthy control. 315 Recent research also stated that a higher level of CD63 + in different cancer types consolidates as a potential biomarker for cancer. 316 CD81, another biomarker, was found to be higher in chronic hepatitis C patients and associated with fibrosis and inflammation. 317−319 In a lung cancer diagnostic biomarker study, authors found a higher expression of CD151, CD171, and tetraspanin 8 in serum exosome blood collected from 581 cancer patients (431 with lung cancer and 150 controls). 320 This study suggests exosomal protein is a promising biomarker for nonsmall-cell lung carcinoma (NSCLC). Glypican-1 (GPC1)-positive exosomes serve as potential biomarkers in early stage pancreatic cancer. Exosomes isolated from systemic circulation of 250 pancreatic patients showed a higher correlation of GPC1 in cancer patients than the healthy control. 321 In another biomarker proteomic study, urine exosomes collected from a mouse liver damage model were utilized. The authors demonstrated that CD26, CD81, S1C3A1, and CD10 could be used as a potential biomarker for hepatic damage. 322 On the same line, a urine exosome biomarker study revealed that some specific markers are most frequently associated with ALG2-interacting protein X (ALIX), CD24, CD9, flotillin-1, HSP70, tumor susceptibility gene 101 (TSG101), lysosome-associated membrane protein 1 (LAMP1), gp330 precursor, uromodulin, pro-epidermal growth factor precursor, MME neprilysin, and beta-galactosidase precursor. 323−329 In a gastric cancer biomarker study, the authors found that metastatic AZ-P7a cells release let-7 miRNA, which activates CD-97-associated pathways to promote oncogenesis. 330−332 Many studies prove that glioblastoma (GBM) is malignant, and exosome mRNA content provides us more insight into GBM and how biomarker identification will lead to an effective treatment. 333 Studies show MiR-21 plays a key role in GBM pathways. Also, exosomal marker noncoding RNA (RNU6−1) and microRNA (miR-320, miR-574−3p) are significantly associated with GBM diagnosis. More evidence shows an exosome role in carcinogenesis pathways such as ERK, PI3K/AKT, STAT3, and PTEN. 333−336 Breast cancer is a highly prevalent disease, and early diagnosis gives a better outcome of treatment. Serum exosome microRNA or noncoding RNA analysis shows promising results in breast cancer biomarker identification. 337 In another study, the authors found exosomal miRNA-21 with 105 expressions higher tissue of metastasis patients than nonmetastasis and healthy donors, which implies that liquid biopsy based on circulating exosomes can be a complementary diagnostic biomarker tool for a breast cancer study. 338 Another plasma exosome analysis study revealed that exosomal microRNA MiR-21 and MiR-1246 are more significantly elevated in human breast cancer patients and can serve as a plasma biomarker for breast cancer.

Exosomes harbor different proteins, lipids, and nucleic acids that are present in most body fluids. It has been proven that exosomes play a role as a critical signal transduction promoter to recipient cells via transporting proteins, lipids, mRNA, microRNA, etc. Research on exosomal biology and functions makes it ideal as a biomarker screening tool. Compared with traditional biomarker specimens such as serum or urine, exosome offers higher sensitivity and specificity to their excellent stability. The use of biomarker screening utilizing exosomes will expand since they are found in mammalian cells and a diverse range of pathological microorganisms. 339−341 In conclusion, exosomes for use as biomarkers are in a very early stage of discovery, and their potential clinical value waits to be fully explored.

5.5. Exosome Applications in Medical Imaging and Tracking. Exosomes were thought to be waste materials from cells until they were revealed to transfer various biomolecules to various cavities. 342 To engage in intercellular communication by overcoming the natural biological barrier (e.g., blood− brain barrier), exosomes have become an emerging effective diagnostic and therapeutic nanocarrier. 13, 343 However, there is a limited understanding of how and where exogenously administered exosomes are distributed in vivo. 344 The current method to assess exosome-mediated delivery success is to evaluate therapeutic symptoms or repeated post-mortem histopathological examination. Therefore, real-time, noninvasive exosome imaging is a prerequisite to making exosomal therapy clinically relevant. In recent years, scientists have developed an efficient labeling and tracking method of exosomes using various imaging modalities ( Figure 8 ). The imaging tools can provide information on exosomes such as biodistribution, migration capability, physiological functions, and in vivo behavior, and enhance the opportunities to find an optimal administration route for exosome-mediated drug delivery. 345 Optical imaging is a widely used imaging and diagnostic technique that is cost-effective, highly sensitive, and includes images at the molecular level. There are mainly two types of optical imaging: fluorescent imaging and bioluminescence imaging. Fluorescence imaging is based on a fluorescence probe that is excited upon the laser irradiation, by which it produces fluorescent signals observed by the optical imaging system. Fluorescence imaging is noninvasive and is used in real time with the use of nonionizing light sources. 346 There are two ways to label exosomes with fluorescent materials (e.g., proteins, dyes, or nanoparticles). (1) Indirect labeling is to have parent cells express a fluorescence protein, including green fluorescent protein or red fluorescent protein, to excrete the exosomes with their biological mechanism of visualization capability passed down to their daughter cells. (2) Direct labeling is another type of labeling in which fluorescence dyes (or nanoparticles) are used to label the secreted exosomes after isolation via surface modification or physical interaction to observe their biodistribution and tissue (7) (DiR) dyes can be used to successfully labeled exosomes derived from breast cancer cells, and the resulting the biodistribution in tumor-bearing xenografts could be observed. In comparison with DiR dyelabeled liposomes, they found most exosomes accumulated in the liver and spleen after 1 h of intravenous injection. They also observed higher fluorescence sensitivity of exosomes than liposomes within tumor regions. 349 Bioluminescence imaging utilizes the natural light emission process from some living organisms that bioluminesce (e.g., firefly, bacteria). Bioluminescence images are generated by detecting photons emitted internally from enzyme-catalyzed reactions with an optical imaging system. 350 The Takakura group from Kyoto University constructed exosomes with intense luciferase activity via indirect labeling. In their study, B16-f10 murine melanoma cells were transfected with the plasmid expressing a fusion protein of gLuc-lactadherin. The secreted exosomes from the cells were collected by the ultracentrifugation isolation method. After a 4-h systemic injection, they found the exosomes accumulated first to the liver and then to the lungs with fast clearance from systemic circulations. 351 Because of the penetration depth limitation of light in optical imaging, ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review other whole-body imaging modalities are needed. Computed tomography (CT) is a crucial imaging technique for disease diagnostics with a high temporal and spatial resolution based on measuring X-ray absorptions throughout the body. X-ray CT imaging has been widely used in the clinic to visualize bone structures and has now been adapted to quantify cell tracking with gold nanoparticle labeling. 352 A recent publication showed that stem cell-derived exosomes labeled with gold nanoparticles could track the migration and homing patterns in brain disorders. 353 Betzer et al. studied the efficient labeling of glucose-coated gold nanoparticles to exosomes and demonstrated the enhanced exosomal accumulation at the lesion site using CT imaging on a mouse model of focal brain ischemia after 24 h of intranasal administration. 354 Gold nanostructures can be potentially used for photoacoustic imaging (PAI) of tracking of exosomes, using strong light absorption to generate sound waves. On the basis of a "light in/sound out" approach, PAI can efficiently combine optical imaging's spectral contrast and the anatomical penetration depth of ultrasound imaging (up to multiple centimeters). 355 Another whole-body imaging technique is magnetic resonance imaging (MRI), which offers advantages with radiation-free, high spatial resolution. To be detected by MRI, exosomes are required to be labeled with superparamagnetic iron oxide nanoparticles (SPIONs). In one study, Hu et al. utilized the electroporation technique to allow melanoma exosomes to be loaded with SPIONs and detected by MRI. They revealed that the SPION-exosome exhibited a much more efficient homing and retention in sentinel lymph nodes than the free SPION 48 h after initial footpad injection. 356 Furthermore, in a newer magnetic imaging modality, magnetic particle imaging (MPI), SPIONs can create a linearly quantifiable signal that is difficult to achieve in MRI without any tissue background signal. In a recent study, Jung et al. labeled SPIONs in MDA-MB-231 cancer cells' culture in hypoxic conditions and showed hypoxic cancer cells take up these exosomes more avidly. They showed these exosomes are quantitatively visualized with MPI signals from SPIONs to monitor the whole-body distribution and in vivo targeting of exosome-mediated drug (Olaparib) delivery to tumors. 357 Exosomes play a pivotal role in analyzing cancer biology and brain diseases. It is crucial to diminish falsepositive exosomal signals from exosome labeling as an imaging tool.

Besides, exosome-based multimodal imaging can be considered more effective and specific for noninvasive disease diagnostics. Cao et al. reported that nucleus-targeted exosome engineered vanadium quantum dots nanocomposites showed effective multimodal (PAI and MRI) image-guided efficient cancer therapeutic potency. 358 Besides, nanocomposites showed good biocompatibility and long circulation time. As a result, it can target a high number of cancer cells and have demonstrated efficacy in escaping the endosome and advancement into the nucleus. Because of their NIR absorbance and good photostability, nanocomposites-treated mice exhibited a 2.11-fold higher PAI signal in the tumor site than the control group. In contrast, because of the 3d1 electronic configuration of quadrivalent vanadium (V) and the quantum mechanical confinement, nanocomposites displayed 3.73-fold higher in vivo T 1 MRI contrast than the control groups. Their overall results indicated that nanocomposites could be attractive agents for multimodal imaging (Figure 9 ). 341 New exosomal imaging techniques will be developed for preclinical and clinical settings with continuous development in the field of exosome research. 5.6. Role of Exosomes in Vaccine Development and Delivery. Almost all living organisms, including viruses and bacteria, shed exosomes in the extracellular matrix. As mentioned before, exosomes carry larger proteins, lipids, and nucleic acids in their cargo. Lipids, proteins, membrane trafficking, nucleic acid-like signal transducers, anti-apoptosis molecules, and T-cell stimulations found on the exosome surface also has some immune-modulatory effects. Exosomes also contain a high level of triacylglycerol (TAG), cardiolipin, and cholesterol (CE), and where TAG and CE are found in the lipid droplet core and cardiolipin in mitochondria. 65 Both cellspecific and ubiquitous proteins are selectively expressed in exosomes from their native cells. They also include cytosolic proteins such as tubulin, flotillin, and membrane transport proteins such as annexin, actin, and Rab proteins 1. Exosomes also carry heat shock proteins such as HSP20, HSP27, HSP70, and HSP90, involved in loading and binding antigen peptide onto MHC molecules, antigen presentation, maturation dendritic cells, and translocation of NF-κβ into the nucleus through CD91. 359, 360 Another abundant protein family present on the exosome surface is tetraspanin like CD9, CD63, CD81, and CD82, interacting with multiple proteins such as integrin and MHC class I and II. 361 Exosomes that are released from viral cells also carry viral miRNA, proteins, and even the entire virion. For example, the major oncoprotein of EVB (a gamma herpesvirus), latent membrane protein 1 (LMP1), was identified in exosomes isolated from EVB infected cells. 362 Immune modulating cells such as macrophages and monocytes abundant with exosomes can modulate antigen presentation and affect myeloid cell differentiation and proliferation. During antigen presentation, B-cell-derived exosomes first interact with antigens and modulate T-cell activation and cytokine secretion. 363, 364 The study also shows that immune-derived exosomes take cytokines such as TGF-β, IL-1α, TNF, and IL-1 β. On the contrary, infected cell-derived exosomes can carry viral molecules and microbials. 365 Exosomes also play a critical role in the chronic inflammatory process. For example, DC-derived exosomes behave as antigen-presenting molecules and can perpetuate Th2 cells' response to DC to regulate immunity and inflammation. 366 Mast and B-cell-derived exosomes also drive Th2 responses and promote the Th2 environment. 367 Exosomes also play a role in processes such as angiogenesis, stromal cell activation, and tumor growth metastasis. The release of exosomes is increased when a cell is under stress, particularly at stress conditions due to disease-related changes. 368 In the current therapeutic paradigms, cancer cells become nonresponsive to chemotherapeutics and radiation after repeated exposures, and exosomes are one of the major players in cancer progression. For example, pancreatic cellderived exosomes carrying tetraspanin-8 promote vessel branching. Tetraspanin-8 also modulates uptake and binding of cancer exosomes by endothelial cells. 369 

cell responses. 301, 371 Therefore, exosomes play both an immune activation and a cancer progress role depending on the cell type origin. However, exosomes also suppress immune cell activation. Studies show that cancer exosomes also elevate the differentiation of mature dendritic cells without its antigen presentation to the myeloid cell, which produces TGF-beta for T-cell suppression. 372 Thus, exosomes use signaling between tumor cells and surrounding cells to promote the tumor microenvironment. In an infectious disease, the pathogen faces a hostile situation and invades cell signaling. Along the same line, the study shows pathogen use of exosomes for differentiation, growth control, transmission, and virulence coordination to infection. For example, exosomes from malaria are actively taken up by endothelium and monocytes, altering vascular properties, promoting virulence via malaria exosomes, and stimulating DNA-sensing pathways via microRNA. 373 Parasite or virus-infected cells or parasites themselves release exosomes to activate immune cells via antigens to present to APC. In contrast, exosomes from microbial molecules carrying leishmania GP63 or HIV Nef can activate apoptosis of immune effector cells like helper T-cells and effector B-cells or inhibit T-cells. 374 Vaccines deliver the natural or inactive form of proper antigens adjuvant; partial viral particles typically elicit a potent immune response. In cancer immunotherapy, a tumorassociated antigen (TAA) can be a potential delivery particle as a vaccine. For vaccine applications, some TAA targeting proteins such as HER2, p53, CEA, RAS, MUC1, etc., are immunosuppressive and poorly antigenic. 375 For example, Hartman et al. has proposed to generate recombinant adenoviral vectors expressing the extracellular domain (ECD) of carcinoembryonic antigen (CEA) or HER2 linked to the C1C2 domain of lactadherin in addition to native unlinked ECD versions of CEA and HER2. The authors found adenoviral expression of a C1C2-modified CEA/ECD, and HER2/ECD resulted in higher expression of the protein in the exosome fraction in transgenic murine model than the control. This study signifies low immunogenicity of soluble TAAs in cancer patients and opens the cancer vaccine platform via improving antitumor immune response. 376 Recently, exosomes are getting much more attention due to their intrinsic properties as drug carriers and immunomodulators. Anticoli et al. has used engineered exosomes with the E7 protein of the human papilloma virus (HPV). The study demonstrates that E7 protein elicited solid and effective antigen-specific cytotoxic T-lymphocyte (CTL) immunity. Genetically engineered autologous or allogeneic T-cells expressing chimeric antigen receptors (CARs) or T-cell receptors (TCRs) as cellular immunotherapy agents are promising as a new treatment method for multiple ranges of cancers. 302 Despite T-cell efficiency, T-cell therapies show unique toxicities such as cytokine release syndrome (CRS) and CAR-T-related encephalopathy syndrome (CRES). Previous studies also showed human T-cell-derived exosomes in cytotoxic Tlymphocyte (CTL)−target cell interactions. 377,378 CTLderived exosomes containing CTL surface membrane molecules (CD3, CD8, and the TCRs) result in tumor cell death as a consequence of interactions between the TCR and proper antigen/MHC combination. The authors' data validate that CAR-containing exosomes derived from CAR-T cells can be used as cancer-targeting agents and can improve the therapeutic efficacy of a potential cancer vaccine platform. 262 Another study by Li et al. demonstrates an exosome derived from Toxoplasma gondii that modulates the immune response. The exosomes were isolated from T. gondii and incubated with macrophage RAW264.7 cells. After T. gondii exosomal treatment, production of IL-12, TNF-α, and IFN-γ in macrophage cells increased, and the level of IL-10 decreased, as determined using an enzyme-linked immunosorbent assay (ELISA). The authors have concluded that T. gondii exosomemodulated macrophage activation in vitro triggers humoral and cellular immune responses and results in partial protection against acute parasite infection in mice. The results suggest that exosomes may serve as a potential candidate against toxoplasmosis. 379 Roier et al. showed how outer membrane vesicles form in Gram-negative bacteria emerging in the research field and significantly impact future applications such as outer membrane vesicle (OMV)-based vaccines. OMVs derived from heterologous H. inf luenza strains were thoroughly characterized for size distribution and quantity of vesicle production among strains Rd KW20, Hib strain Eagan, and NTHi 2019-R strain. The presence of vaccine candidate 13 ATP-binding cassettes (ABC) transporter proteins and 8 lipoproteins in H. influenzae OMVs supports their potential to act as a vaccine against H. inf luenzae infections. In contrast, the presence of essential virulence factors such as serine protease HtrA and vaccine candidates OMP 26 and protein D indicates that OMVs in H. influenza pathogenesis have potential vaccine application via exosome. 380 This above discussion demonstrates that the exosomes can play an important role in immune modulation, serve as potential vaccine development platforms, and be used as a delivery vehicle. Exosomes can increase the efficiency of vaccines to generate antibodies against multiple diseases and are a versatile platform for developing more vaccines.

In the preclinical study discussion, we found exosomes play a critical role in both physiological and pathological conditions, as they can carry pathogenic messages that indicate disease condition. Therefore, exosomes can be utilized as a biomarker and a disease marker to target for therapeutic efficiency. Preclinical studies of exosomes for use as a biomarker, in early detection and drug delivery methods, and in vaccine development platform make them suitable candidates in clinical settings. We believe exosomes can link bridges between our knowledge gaps in different disease conditions. The preclinical data show that exosomes have the potential for application in cancer immunotherapy, infectious disease, and brain disease treatment.

The wide range of biological content found and released from exosomes in physiological conditions has various applications in biomedical and drug delivery contexts, such as finding new biomarkers, creating new imaging tools, and developing therapeutic carriers for cancers and brain disease. Up until January 2021, we have found 205 clinical trials related to exosomal research. Out of 205 trials, around 87 trials involve cancer-related studies, 18 include brain pathologies, and 100 include diabetic, cardiovascular, lung, or kidney diseases, including a novel coronavirus study. In cancer-related trials, there are about 87 clinical trials in the pipeline. The trials include using exosomes for various processes, such as studies on angiogenesis, tumor growth metastasis, and stromal cell activation, and facilitating cancer progression. 368 When a tumor starts growing, it quickly becomes hypoxic, which triggers the regulation factors of both pro-angiogenic and antiangiogenic cytokines like vascular endothelial, fibroblast, pericytes, and endothelial growth factors (EGF). 381, 382 Exosomes are one of the key players in cancer progression, drug resistance, 383 and prognosis. 384, 385 For example, pancreatic cell-derived exosomes carrying tetraspanin-8 promote vessel branching. Tetraspanin-8 also modulates the binding and uptake of cancer exosomes by endothelial cells. 30 Al-Nedawi et al. found lung cancer exosomes delivered mutated EGF receptor to pulmonary endothelial cells, activating EGF receptor, and signaling through AKT and MAP kinase pathways. This activation is misleading to VEGF secretion and endothelial cell response to tumor progression. 386 Therefore, cancer cell-derived exosomes can provide effective treatment of antiangiogenic therapy. 387 Lucero et al. demonstrated glioblastoma (GBM) cell-derived exosomes deliver angiogenic mRNA and translate it to protein into recipient cells. 388 Authors identified possible GBM exosomal mRNA as a liquid biopsy biomarker, which shows a trace of post-transcriptional gene silencing. Another study found colorectal exosomes deliver angiogenic mRNA to endothelial cells and enhance proliferation of tubular formation. 389 With angiogenic mRNA transfer via interaction with α4 and β1 integrins, angiogenesis is stimulated via eNOS and the PI3K/ AKT signaling pathway. Table 1 shows clinical trials based on the use of exosomes as a diagnostic tool, biomarkers, and therapeutic intervention for cancer research. Early detection is a powerful tool to fight against cancer progression. In early detection statistics, there was more than a 70% mortality decrease due to early detection and identification of novel markers of cancer. Exosomes have been used as a biomarker for cancer for decades. That is why we found more than 50 clinical studies of multiple phases looking for biomarkers like protein expression, mRNA, tumor-circulating exosomes, and tumor-derived exosomesthe first study was based on exosomes role as a therapeutic tool for those with advanced unresectable or metastatic melanoma. Exosomes from senescent melanoma cells will be utilized to study the process of drug resistance and relapse, as a therapeutic tool for melanoma for personalized medicine for patients. Another study in Table 1 (No. 4), in early lung cancer research, uses a blood sample exosome of lung cancer patients for identifying biomarkers (NCT03542253). 390 No. 8 in the table will use urine exosomes, utilizing clear cell renal cell carcinoma to identify diagnostic biopsy tools for early detection (NCT04053855). Another study on proteinosis gallbladder carcinoma uses the blood exosome as a biomarker for a correlation study (NCT03581435). 391 In breast neoplasm, tumor-derived exosomes are used as diagnostic and prognostic markers against receiving neoadjuvant chemotherapy (NCT01344109). 392 In gastric cancer, gastric cancer-derived exosomes are used as diagnostic tools for early detection (NCT01779583). 393 In bone metastasis, scientists also utilize circulating tumor exosomes to identify deregulated miRNAs as a biomarker for use in subsequent bioinformatic tool development (NCT03895216). 394 Another study on carcinoma ovarian cancer was based on the analysis of miRNA and lncRNA expression in exosomes. 395 These biomarkers will be employed as biomarkers for early detection as well (NCT0373831).

Other examples include a lung cancer study (NCT03830619), prostate cancer biomarker correlation study (NCT03911999), renal fibrosis study based on urine exosome biomarkers (NCT03870542), nonsmall lung cancer biomarker study for early detection (NCT02921854), and a colorectal cancer biomarker study using blood exosome samples (NCT04394572). These clinical studies have been in multiple phases, and success in these studies will accelerate current cancer treatment many folds. Another cancer research topic uses exosomes in a clinical study to deliver and measure certain drugs' effectiveness in cancer treatment. For example, a review of MK-3475 (Pembrolizumab) on the triple-negative breast tumor microenvironment analyzing both primary tumor, normal breast stroma, circulating lymphocytes, and serum exosomes are in Phase 1 (NCT02535247). Another study on NK and T-cell non-Hodgkin lymphoma, using MK-3475 alone or in combination with copanlisib, analyzes PD-1 expression of peripheral blood lymphoma and T-cell exosomes in Phases 1 and 2 (NCT02535247). Another study on thyroid cancer (NCT03109847) targets the side effects of radioactive iodine treatment of differentiated thyroid cancer, aiming to mitigate them using Metformin hydrochloride validated by serum and saliva exosomes in Phase 2. Another exciting research study is based on patients with stage II−IV squamous cell cancer of the head and neck using Nivolumab and BMS986205, designed to analyze the abundance of exosomes and composition in the peripheral blood for identifying exosomal biomarkers. This study is in Phase 2 with clinical identification number NCT03854032. The last review we will discuss here is colorectal cancer patients with oligometastasis. The study used Ripalimab plus stereotactic body radiotherapy for clinical therapeutic intervention. It is also a Phase 2 study and identification number NCT03927898. 396 Other drug analysis studies based on exosome applications include a study on MDM2 inhibitor AMG-232 treating soft tissue sarcoma (NCT03217266) and another on evaluating the efficacy of Olmutinib using DNA extracted from exosomes of bronchoalveolar lavage fluid on T790M-positive nonsmall-cell lung cancer (NCT03228277). These drug efficiency studies using exosomes give the researcher a suitable and versatile option for treatment. Most of these drug testing studies are either in Phase 1 or 2 and show promising data. Additional exciting applications of exosomes are in vaccines and cancer imaging. In the previous section, we discussed exosomes' immune modulation capabilities and antitumor properties. We found some studies of exosomes for use in vaccine applications. One study used tumor antigen-loaded dendritic cell-derived exosomes as vaccination candidates for nonsmall-cell lung cancer immunotherapy. This is a Phase 2 study with successful Phase 1 data on lung cancer patients and identification number NCT01159288. In the case of imaging and early detection, exosomes also play a promising role. For example, a study combined CT and exosome diagnosis in early lung cancer and found exosomal micro-A was highly expressed in early stage lung cancer tissues and was significantly higher than paracancerous tissues (NCT03542253). The subsequent study dealt with metastatic, castrate-resistant prostate cancer using the detection of ARv7 in the plasma through blood sample analysis (NCT03236688). Another study used ultrahighresolution optical coherence tomography in detecting micro- Exosome-based cancer immunotherapies show very promising outcomes that can translate as clinically applicable products in the near future. 6.2. Clinical Trials Addressing Brain and Inflammation Diseases. In a brain disease and inflammation study, we found a total of 19 clinical study designs (Table 2) . Penetrating the BBB and delivering drugs or active biologics is an interesting area for more more investigation because of the unique challenges. From our prior discussion, exosomes are suitable candidates for detection and drug delivery for brain diseases. For example, MSC-derived exosomes enriched with miR-124 are used in treating cerebrovascular disorders (NCT03384433). A previous study on MSC-derived exosomes shows promising data on wound healing, cell-free therapy against lung fibrosis, and skeletal muscle regeneration. 397, 398 The next promising study is a biomarker study on Parkinson's disease. The study identifies LRRK2 and other novel exosomal protein expressions utilizing exosome biomarker screening (NCT01860118). Another study on Parkinson's disease estimates the prevalence of ARMD in a sample of Parkinson's patients and identifies the correlation between L-DOPA treatment and ARMD (NCT01860118). In an Alzheimer's disease study, curcumin's benefits due to the inhibition of several potential disease pathways in Alzheimer's disease and exosomes are employed in analyzing potential therapeutic applications (NCT01811381). In this trial, the investigator looked for specific blood biomarker changes due to curcumin and yoga's combined effect. Another Alzheimer's disease therapeutic application is allogenic adipose MSC-exosome safety and efficacy in Alzheimer's patients with mild to moderate dementia for improving cognitive function (NCT04388982). Investigators also look for abnormal kidney and liver function due to exosomal treatment. The next study in Table 2 focuses on using exosomes to enhance the delivery of anti-inflammatory agents and growth factors to targets by using focused transcranial ultrasound for neuralgia before intravenous infusion of exosomes (NCT04202783). In this trial, the investigator utilizes a brief pain inventory (BPI) scale to measure the pain due to transcranial ultrasound treatment. 399, 400 For cancer immunotherapy of malignant glioma neoplasms, a comparative Phase 1 study with conventional treatment and a boost with immunotherapy used brain cancerderived exosomes (NCT01550523). Scientists isolate the patient's tumor cells and treat them with an antisense molecule (IGF-1R/AS ODN) to remove a targeted tumor receptor on the tumor cells' surface. After reimplanting the treated cells in the same patients, tumor cells are activated apoptosis and released exosome-carrying tumor antigens. Because of antigen release, T-cells are activated to eliminate the tumor. By training our immune system to recognize tumors in the future, the patient will be protected from another tumor invasion via immune surveillance. 401, 402 Preclinical data reveal that exosomes can cross the BBB and deliver payload within the brain. Thus, exosomes have the immense possibility of overcoming the therapeutic drawbacks of brain-related diseases.

6.3. Clinical Trials of Immune, Heart, Lung, Diabetes, Kidney, and Blood Diseases. In Table 3 , we compiled multiple disease applications of exosomes either as biomarkers, diagnostics, therapeutics, or vaccine applications. We found a total of 100 clinical studies on type 2 diabetes, cardiovascular research, kidney, lung, heart diseases, ulcers, hypertension, etc. Here we will describe some essential studies to give a concise description of the clinical research. For example, for ulcer patients, investigators utilize plasma-derived exosomes on cutaneous wound healing (NCT02565264). In this trial's preclinical study, scientists found serum-derived exosomes accelerate cutaneous wound healing in the BALB/c mice model. Scientists conclude from that study that exosome supplements to cutaneous ulcer diseases such as peripheral arterial disease, decubitus, or burns have a significant therapeutic effect, and serum exosomes that will be collected from the patient's own body will have more acceptance as a therapeutic. 403, 404 The following study is on umbilical cord blood MSC-derived exosomes on β-cells masses in type I diabetes mellitus (NCT02138331), now in Phase 2 and 3. Authors conclude that cell-free umbilical cord-blood-derived MSC exosomes may improve the inflammatory state and enhance β-cell mass of the pancreases along with glycemic control. 405 In the preclinical study of the trial, the authors observed that transplantation of MSC correlates to an increase in T-regulatory cells and both local and systemic reduction of autoaggressive T-cell populations, i.e., the shift of cytokine profile from pro-inflammatory to anti-inflammatory type. Furthermore, MSC transplantation increases local pancreatic cell number and increases circulating epidermal growth factor (EGF). EGF lowers blood glucose and increases insulin secretion. 406 In both a type 1 and type 2 diabetes mellitus study, circulating exosomes from β-cells were analyzed for biomarkers and therapeutic targets. 407−410 There is a study on preeclampsia, where the exosomes of peripheral blood will be compared to umbilical cord mesenchymal stem cells to identify miRNAs 136, 494, and 495 gene expression (NCT03562715, Table 3 , No. 14). This specific trial is an example of biomarker screening utilizing the exosome profile. Recent data suggest that exosomes released from the placenta carry specific cargo responsible for causing preeclampsia. Isolating exosomes from the placenta and maternal blood and analyzing their biochemical and molecular mechanisms can provide important insight into the novel therapeutic intervention of preeclampsia associated with cardiovascular disease in normal and complicated pregnancies. 411−414 In another study based on exosomes, chronic kidney failure treatment is conducted using hemodiafiltration (OL-HDF), and analyzing mRNA expression of serum exosomes (NCT03202212). MicroRNA content analysis of exosomes using RT-qPCR will give insight into any inflammatory markers due to treatment against chronic kidney disease. Obesity is another significant health care burden. Exosomes have also been studied for the development of a potential obesity treatment. 415 In the current study, to determine how meal timing affects these end points differentially during the daytime and nighttime, urine exosomes will be analyzed in 12-h bins (NCT03459703, Table 3, No. 30) . In this study, investigators will evaluate how mealtime influence obesity by conducting multiple behavioral studies such as mood state, retention, depression, loneliness, appetite, adherence, urine content analysis (oxalate, sodium, potassium, creatinine, nitric oxide, albumin, nephrin, KIM-1), and urine exosomeal mRNA and microRNA content. 416, 417 In a COPD ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review study, exosome expression alteration was analyzed on epigenetic, mRNA, miRNA content using RT-qPCR and exosome profiling (NCT03049202 and NCT04183530, Table  3 , Nos. 34 and 63). In both trials, the authors utilize exosomes from saliva, serum, urine, blood, and stool sources for biomarker analysis.

In preclinical studies of COPD, the authors identified either circulating exosomes content or microRNA expression (e.g., MiR-21) in analyzing specific pathways related to COPD. 418, 419 These identified markers can be used as diagnostic or therapeutic targets for novel therapeutics against COPD. In HIV and tuberculosis also, clinical trials currently underway use the exosomal platforms. The study design analyzed changes in serum and tissue exosomal miRNA expression in HIV and tuberculosis patients for early detection for biomarkers (NCT03941210). In the current situation, COVID-19 has been spread worldwide, and still, outbreaks continue due to a lack of knowledge of its pathogen and vaccine absence. Scientists are working relentlessly to find a cure against SARS-CoV-2. We found four COVID-19 related clinical trials already based on the exosome platform, which confirms the exosome's versatile application and capability.

The first one seeks to evaluate the safety and potential efficacy of Organicell flow Zofin via exosome analysis (NCT04384445). Zofin is a cellular product derived from human amniotic fluid. It contains over 300 growth factors, chemokines, cytokines, and exosomes derived from epithelial and amniotic cells. Surface marker analysis reveals the presence of exosome-associated proteins CD9, CD133, CD63, and CD81, and completed sequencing revealed 102 commonly expressed miRNA. Major pro-inflammatory cytokines targeted by miRNA found in Zofin include TNF, IL-6, IL-8. Other targeted cytokines are VEGFA, IGF-1, FGF2, IL36a, CCL8, CXCL12, and IL37. Many published articles suggest that suppressing the above-mentioned pro-inflammatory cytokines cascade will reduce the severity of elevated immune response. 420−424 The next trial is in patients with severe novel coronavirus pneumonia (NCP) to evaluate the safety and efficiency of aerosol inhalation of exosomes derived from allogeneic adipose mesenchymal stem cells (MSCs-Exo) (NCT04276987). Human adipose MSCs-derived exosomes (hASCs-Exo) can stimulate T-cells in vitro and inhibit IFN-γ release and T-cell proliferation. Thus, hASCs-Exo can be considered as a therapeutic against inflammation-related diseases. 425−427 The last trial is to test the safety and efficacy of T-cell-derived exosomes following targeted delivery by metered-dose inhaler on coronavirus patients. Investigators collect donor origin COVID-19-specific T-cells and expand them via viral peptide fragments with cytokines present. This will activate the T-cells, and stimulation will cause the release of IFN-ϒ in exosomes. 428−431 All these coronavirus studies are based on vaccine development clinical trials, and hopefully, we will see commercialized vaccines based on the exosome platform. We already have the coronavirus vaccines from Moderna and Pfizer-BioNTech, and these vaccines were made available to the general public in January 2021. A third vaccine from Janssen also got emergency use authorization on February 27, 2021. However, there have been reporting of a very rare and serious blood clot in people who receive the Janssen vaccine. The Oxford COVID-19 vaccine shows a robust immune response in adults of 60−70 years old. Phase 3 studies show the vaccine to be 76% effective at preventing COVID-19 infection. Table 3 also focuses on obesity, type 1 and 2 diabetes, obesity, cardiac disease, organ failure, hypertension, atrophy, muscle dystrophy, and an exosome study on insulin resistance application. Hopefully, this section can give a proper rationale for exosome application in disease diagnosis, biomarker screening, and therapeutic application phases.

We can see that exosomes have intrinsic advantages over traditional delivery methods, biomarker analysis, diagnosis, and medical imaging application from the three tables above. Even while some polymeric nanoparticles have been commercialized, exosomes still hold a better future in drug delivery and vaccine development. Recent studies also expect exosomebased personalized medicine for patients with cancer, neurodegenerative, and inflammatory diseases. Exosomes will answer many unknowns of the multiple conditions for which proper treatment or diagnosis is not available yet.

With substantial development of this field in the last two decades, exosomes bring us more possibilities in multiple deadly disease treatments and diagnosis. Although therapies are under development, we still do not know the exact mechanism of biogenesis. Isolation techniques for exosomes are tedious and hard to translate to the clinical setting. We found multiple commercial exosome isolation kits available; still, we need considerable progress in this technology. Once we identify a universal isolation method, we can correlate clinical outcomes all over the world. The validation of promising findings by scientists is impossible until we have a unified isolation and characterization method in place. In our clinical review section, we found that, as of now, 205 clinical trials have been conducted based on exosome application. However, because of complexities and variations in methodologies, the reproducibility of the exosome is widely varied, which presents difficulties for interpretation of results. Therefore, we need standard operating procedures (SOPs) for exosome isolation, storage, characterization, and analysis. With more in-depth knowledge of biogenesis and function, exosomes will open up significant opportunities in therapeutic application, and already recent studies have investigated exosomes as a biomarker and natural gene/drug delivery system. In conclusion, we urgently need an efficient and reliable isolation method to advance this research field.

Exosomes are widely disseminated and heterogeneous entities. However, exosome complexity is not thoroughly understood, especially the mechanisms responsible for sorting cargo into exosomes and releasing cargo into cells after exosome internalization. While many recent studies have focused on protein sorting in exosomes, executive functions might be associated with RNA delivery. Therefore, determining the mechanism that underlies RNA sorting in the exosomes holds excellent potential for developing various therapeutic applications. Because of their various advantages over traditional nanoparticles, exosomes are more than viable candidates for targeted drug delivery innovation. In clinical trials so far, most applications of exosomes are in their use as biomarkers.

Exosomes have slowly garnered more attention in the drug delivery field due to their natural origins and the protein/ lipids/receptors present on their surface. Besides, some research groups have taken this even further by working on exosome surface modification through genetic alterations, DNA tethers, etc. However, the clinical application of current exosome research is the scope of this review. These inquiries into the exosomes provide a field ripe for further innovation and exploration. In the future, more investigations will need to be conducted into both the physiological and pathological conditions and the mechanisms that interface with the release of exosomes and impairment of exosome-mediated cell−cell communication, which may prove to be the basis of a new class of personalized therapeutics. ■ ABBREVIATIONS Aβ, amyloid beta; ABC, accelerate blood clearance; BBB, blood−brain barrier; BMVEC, brain microvascular endothelial cells; CD8, cluster of differentiation 8; CDC, cardiospherederived cells; CRISPR, clustered regularly interspaced short palindromic repeats; CSF, cerebrospinal fluid; CT, computed tomography; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; EAAT, excitatory amino acid transporters; EGF, epidermal growth factor; ESCRT, endosomal pathways are associated with endosomal complex; GPC, gel permeation chromatography; IL-10, interleukin 10; ILV, intraluminal vesicle; MDSC, myeloid-derived suppressor cells; MHC-1, major histocompatibility complex class 1; MPS, mononuclear phagocyte system; MVBs, microvesicles; mRNA, messenger ribonucleic acid; miRNA, micro ribonucleic acid; MWCO, molecular weight cutoff; MSC, mesenchymal stromal cell; NK cell, natural killer cell; PD-L1, programmed death-ligand 1; RES, reticuloendothelial system; TEX, tumor-derived exosomes ■ REFERENCES

Exosomes: Biogenesis, Biologic Function and Clinical Potential

The Exosome-Derived Biomarker in Atherosclerosis and Its Clinical Application

Exosome Nanotechnology: An Emerging Paradigm Shift in Drug Delivery

Using Exosomes, Naturally-Equipped Nanocarriers, for Drug Delivery

Preformed Albumin Corona, a Protective Coating for Nanoparticles Based Drug Delivery System

Polymers for Drug Delivery Systems

Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors

Could Bioengineered Exosome-Mimetic Nanovesicles Be an Efficient Strategy for the Delivery of Chemotherapeutics?

Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis

Challenges in the Development and Establishment of Exosome-Based Drug Delivery Systems

Fate of the Transferrin Receptor during Maturation of Sheep Reticulocytes in Vitro: Selective Externalization of the Receptor

Exosomes as Reconfigurable Therapeutic Systems

Potential Role of Exosomes in the Pathophysiology, Diagnosis, and Treatment of Hypoxic Diseases

Exosome-Based Cell-Cell Communication in the Tumor Microenvironment. Front

Unidirectional Transfer of MicroRNA-Loaded Exosomes from T Cells to Antigen-Presenting Cells

Dendritic Cell-Derived Exosomes in Cancer Immunotherapy: Exploiting Nature's Antigen Delivery Pathway

Exosome-Based Tumor Antigens−Adjuvant Co-Delivery Utilizing Genetically Engineered Tumor Cell-Derived Exosomes with Immunostimulatory CpG DNA

Exosome Engineering for Efficient Intracellular Delivery of Soluble Proteins Using Optically Reversible Protein−Protein Interaction Module

The Origin and Functions of Exosomes in Cancer

Analysis of the RNA Content of the Exosomes Derived from Blood Serum and Urine and Its Potential as

Exosome Function: From Tumor Immunology to Pathogen Biology

Exosomes as Therapeutic Drug Carriers and Delivery Vehicles across Biological Membranes: Current Perspectives and Future Challenges

Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases?

The Carrying Pigeons of the Cell: Exosomes and Their Role in Infectious Diseases Caused by Human Pathogens

Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis

Circular RNA Is Enriched and Stable in Exosomes: A Promising Biomarker for Cancer Diagnosis

Double-Stranded DNA in Exosomes: A Novel Biomarker in Cancer Detection

Exosomes in the Pathogenesis, Diagnostics and Therapeutics of Liver Diseases

Exosomes and the Kidney: Prospects for Diagnosis and Therapy of Renal Diseases

Exosomes: Therapy Delivery Tools and Biomarkers of Diseases

Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation

ExoCarta: A Web-Based Compendium of Exosomal Cargo

Augmented Liver Targeting of Exosomes by Surface Modification with Cationized Pullulan

Surface Modification of Gold Nanoparticles with Neuron-Targeted Exosome for Enhanced Blood−Brain Barrier Penetration

Surface Functionalization of Exosomes Using Click Chemistry

Molecular Recognition-Based DNA Nanoassemblies on the Surfaces of Nanosized Exosomes

Exosomes Transfer Among Different Species Cells and Mediating MiRNAs Delivery

Extracellular Vesicles and Infectious Diseases: New Complexity to an Old Story

Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery

Biodistribution of PLGA and PLGA/Chitosan Nanoparticles after Repeat-Dose Oral Delivery in F344 Rats for 7 Days

A Doxorubicin Delivery Platform Using Engineered Natural Membrane Vesicle Exosomes for Targeted Tumor Therapy

Exosomes as Drug Delivery Vehicles for Parkinson's Disease Therapy

50) Schiffelers, R.; Kooijmans, S.; Vader; van Dommelen; van Solinge. Exosome Mimetics: A Novel Class of Drug Delivery Systems

Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids

Comparison of Serum Exosome Isolation Methods for MicroRNA Profiling

Blood Exosomes as a Tool for Monitoring Treatment Efficacy and Progression of Neurodegenerative Diseases

Macrophage Exosomes as Natural Nanocarriers for Protein Delivery to Inflamed Brain

Functional Delivery of Viral MiRNAs via Exosomes

Engineering Exosomes as Refined Biological Nanoplatforms for Drug Delivery

Dynamic Biodistribution of Extracellular Vesicles in Vivo Using a Multimodal Imaging Reporter

The Contribution of Phagocytic Activity of Liver Macrophages to the Accelerated Blood Clearance (ABC) Phenomenon of PEGylated Liposomes in Rats

Exosomes for Drug Delivery  a Novel Application for the Mesenchymal Stem Cell

A Comprehensive Overview of Exosomes as Drug Delivery Vehicles  Endogenous Nanocarriers for Targeted Cancer Therapy

Curcumin-Primed Exosomes Potently Ameliorate Cognitive Function in AD Mice by Inhibiting Hyperphosphorylation of the Tau Protein through the AKT/GSK-3β Pathway

Molecular Mechanisms of the Membrane Sculpting ESCRT Pathway. Cold Spring Harbor Perspect

Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes

ESCRTs Are Everywhere

Biogenesis and Secretion of Exosomes

Analysis of ESCRT Functions in Exosome Biogenesis, Composition and Secretion Highlights the Heterogeneity of Extracellular Vesicles

Mechanisms Associated with Biogenesis of Exosomes in Cancer

Exosome Secretion of Dendritic Cells Is Regulated by Hrs, an ESCRT-0 Protein

Biogenesis and Function of Multivesicular Bodies

Membrane Scission by the ESCRT-III Complex

Mutation of SIMPLE in Charcot−Marie−Tooth 1C Alters Production of Exosomes

Syndecan−Syntenin−ALIX Regulates the Biogenesis of Exosomes

Syntenin and Syndecan in the Biogenesis of Exosomes

Lipids and Lipid Modifications in the Regulation of Membrane Traffic

Membrane Curvature at a Glance

Lipids in Exosomes: Current Knowledge and the Way Forward

Exosomal Lipid Composition and the Role of Ether Lipids and Phosphoinositides in Exosome Biology

Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells

Cellular Uptake of Extracellular Vesicles Is Mediated by Clathrin-Independent Endocytosis and Macropinocytosis

Arginine-Rich Cell-Penetrating Peptide-Modified Extracellular Vesicles for Active Macropinocytosis Induction and Efficient Intracellular Delivery

Cancer Exosomes Trigger Fibroblast to Myofibroblast Differentiation

Regulation of Exosome Release by Glycosphingolipids and Flotillins

Extracellular Vesicles: Exosomes, Microvesicles, and Friends

Proteomic Comparison Defines Novel Markers to Characterize Heterogeneous Populations of Extracellular Vesicle Subtypes

Multivesicular Endosome Biogenesis in the Absence of ESCRTs

An Emerging Focus on Lipids in Extracellular Vesicles

Role of Sphingolipids in the Biogenesis and Biological Activity of Extracellular Vesicles

Sphingolipid Composition of Circulating Extracellular Vesicles after Myocardial Ischemia

Separation and Characterization of Late Endosomal Membrane Domains

EGF Stimulates Annexin 1-Dependent Inward Vesiculation in a Multivesicular Endosome Subpopulation

MHC Class II-Associated Proteins in B-Cell Exosomes and Potential Functional Implications for Exosome Biogenesis

Exosomal Cargo-Loading and Synthetic Exosome-Mimics as Potential Therapeutic Tools

Syntenin-ALIX Exosome Biogenesis and Budding into Multivesicular Bodies Are Controlled by ARF6 and PLD2

Multivesicular Body Formation Enhancement and Exosome Release during Endoplasmic Reticulum Stress

Exosomes and Autophagy: Coordinated Mechanisms for the Maintenance of Cellular Fitness

Exosome Secretion Is Enhanced by Invadopodia and Drives Invasive Behavior

Exosomes: A Common Pathway for a Specialized Function

Nonclassical IL-1β Secretion Stimulated by P2 × 7 Receptors Is Dependent on Inflammasome Activation and Correlated with Exosome Release in Murine Macrophages

Exosomes and Immune Response in Cancer: Friends or Foes?

Molecular Mechanisms and Clinical Applications of Angiogenesis

Exosomes as Nano-Theranostic Delivery Platforms for Gene Therapy

Diverse Subpopulations of Vesicles Secreted by Different Intracellular Mechanisms Are Present in Exosome Preparations Obtained by Differential Ultracentrifugation

Purification of Molecularly Bridged Metal Nanoparticle Arrays by Centrifugation and Size Exclusion Chromatography

A Protocol for Exosome Isolation and Characterization: Evaluation of Ultracentrifugation, Density-Gradient Separation, and Immunoaffinity Capture Methods

Progress in Exosome Isolation Techniques

Optimized Exosome Isolation Protocol for Cell Culture Supernatant and Human Plasma

Charge-Based Precipitation of Extracellular Vesicles

Ciliated Micropillars for the Microfluidic-Based Isolation of Nanoscale Lipid Vesicles

Isolation of Extracellular Vesicles: General Methodologies and Latest Trends

Isolation of Exosomes by Differential Centrifugation: Theoretical Analysis of a Commonly Used Protocol

A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents

Preparative and Analytical Ultracentrifugation

Isolation of Exosomes by Differential Centrifugation: Theoretical Analysis of a

From Internal Vesicle of the Multivesicular Body to Intercellular Signaling Device

Surface Functionalized Exosomes as Targeted Drug Delivery Vehicles for Cerebral Ischemia Therapy

Ischemic Preconditioning Potentiates the Protective Effect of Stem Cells through Secretion of Exosomes by Targeting Mecp2 via

Protein Refolding at High Concentration Using Size-Exclusion Chromatography

Optimizing Exosomal RNA Isolation for RNA-Seq Analyses of

Analysis of Proanthocyanidins by High-Performance Gel Permeation Chromatography

Microfluidic Isolation and Transcriptome Analysis of Serum Microvesicles

Analysis of Antigen Presenting Cell Derived Exosomes, Based on Immuno-Magnetic Isolation and Flow Cytometry

Comparison of Ultracentrifugation, Density Gradient Separation, and Immunoaffinity Capture Methods for Isolating Human Colon Cancer Cell Line LIM1863-Derived Exosomes

Exosome Isolation for Proteomic Analyses and RNA Profiling

Characterization of Plasma-Derived Extracellular Vesicles Isolated by Different Methods: A Comparison Study

Comparison of Isolation Methods of Exosomes and Exosomal RNA from

Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method

Comparison of Commercial Exosome Isolation Kits for Circulating Exosomal MicroRNA Profiling

Characterisation of Exosomes Derived from Human Cells by Nanoparticle Tracking Analysis and Scanning Electron Microscopy

A Review of Exosome Separation Techniques and Characterization of B16-F10 Mouse Melanoma Exosomes with AF4-UV-MALS-DLS-TEM

Characterization and Comprehensive Proteome Profiling of Exosomes Secreted by Hepatocytes

Tamm-Horsfall Protein and Urinary Exosome Isolation

Mass Spectrometry-Based Proteome Profiling of Extracellular Vesicles and Their Roles in Cancer Biology

Sizing and Phenotyping of Cellular Vesicles Using Nanoparticle Tracking Analysis

Comparative Proteomics Using 2-D Gel Electrophoresis and Mass Spectrometry as Tools to Dissect Stimulons and Regulons in Bacteria with Sequenced or Partially Sequenced Genomes

Mass-Spectrometry-Based Molecular Characterization of Extracellular Vesicles: Lipidomics and Proteomics

Protein Content and Functional Characteristics of Serum-Purified Exosomes from Patients with Colorectal Cancer Revealed by Quantitative Proteomics

Comprehensive Proteomics Analysis of Exosomes Derived from Human Seminal Plasma

Recent Advancements in the Use of Exosomes as Drug Delivery Systems

Exosome Engineering: Current Progress in Cargo Loading and Targeted Delivery

Development of Exosome-Encapsulated Paclitaxel to Overcome MDR in Cancer Cells

Interleukin 3-Receptor Targeted Exosomes Inhibit in Vitro and in Vivo Chronic Myelogenous Leukemia Cell Growth

Large-Scale Generation of Functional MRNA-Encapsulating Exosomes via Cellular Nanoporation

In Vitro and in Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with MiRNA or CRISPR/DCas9

Virus-Mimetic Fusogenic Exosomes for Direct Delivery of Integral Membrane Proteins to Target Cell Membranes

Exogenous DNA Loading into Extracellular Vesicles via Electroporation Is Size-Dependent and Enables Limited Gene Delivery

Evaluation of Electroporation-Induced Adverse Effects on Adipose-Derived Stem Cell Exosomes

Delivery of Small Interfering RNAs to Cells via Exosomes BT

Saponins as Cytotoxic Agents: A Review

Active Loading into Extracellular Vesicles Significantly Improves the Cellular Uptake and Photodynamic Effect of Porphyrins

Enhanced Loading of Functional MiRNA Cargo via PH Gradient Modification of Extracellular Vesicles

Recent Advancements in the Loading and Modification of Therapeutic Exosomes

Challenges in the Development and Establishment of Exosome-Based Drug Delivery Systems

Role of Exosomes in Immune Regulation

Exosomes and Their Roles in Immune Regulation and Cancer

Role of Exosomes in Tumour and Transplant Immune Regulation

MHC Class I-Mediated Exogenous Antigen Presentation by Exosomes Secreted from Immature and Mature Bone Marrow Derived Dendritic Cells

Exosomes Function in Antigen Presentation during an in Vivo Mycobacterium Tuberculosis Infection

Curcumin Reverses Breast Tumor Exosomes Mediated Immune Suppression of NK Cell Tumor Cytotoxicity

Tumor Exosomes Block Dendritic Cells Maturation to Decrease the T Cell Immune Response

Late Endosomes: Sorting and Partitioning in Multivesicular Bodies

Exosomal Membrane Molecules Are Potent Immune Response Modulators

Nanoparticle-Induced Exosomes Target Antigen-Presenting Cells to Initiate Th1-Type Immune Activation

Formation and Role of Exosomes in

Exosome-Delivered MicroRNAs Modulate the Inflammatory Response to Endotoxin

Exosomes as Nanocarriers for Immunotherapy of Cancer and Inflammatory Diseases

Exosomes From Adipose-Derived Stem Cells Attenuate Adipose Inflammation and Obesity Through Polarizing M2Macrophages and Beiging in White Adipose Tissue

The Role of Exosomes in the Pathogenesis of Alzheimer' Disease

Biological Properties of Extracellular Vesicles and Their Physiological Functions

Stem Cell-Derived Exosome in Cardiovascular Diseases: Macro Roles of Micro Particles

Role of Cardiac Progenitor Cell-derived Exosome-mediated MicroRNA-210 in Cardiovascular Disease

Roles of Exosomes Derived From Immune Cells in Cardiovascular Diseases

Exosomes in Immunoregulation of Chronic Lung Diseases

Regulation of Immune Responses by Extracellular Vesicles

Exosomes Biological Significance: A Concise Review

Exosomal PD-L1 Contributes to Immunosuppression and Is Associated with Anti-PD-1 Response

Prions and Exosomes: From PrPc Trafficking to PrPsc Propagation

Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling

Tumour-Derived Exosomes and Their Role in Cancer-Associated T-Cell Signalling Defects

Immune Modulation of T-Cell and NK (Natural Killer) Cell Activities by TEXs (Tumour-Derived Exosomes)

Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion

Anti-PD-1/PD-L1 Therapy of Human Cancer: Past, Present, and Future

Immune Checkpoint Inhibitors of PD-L1 as Cancer Therapeutics

Regulatory T Cell-Based Therapies for Autoimmunity

Imbalance of Regulatory T Cells in Human Autoimmune Diseases

Role of Exosomes in the Regulation of T-Cell Mediated Immune Responses and in Autoimmune Disease

Recent Advances in the Use of Exosomes in Sjogren's Syndrome

Mesenchymal Stromal Cell Exosome-Enhanced Regulatory T-Cell Production through an Antigen-Presenting Cell-Mediated Pathway

The Blood−Brain Barrier. Cold Spring Harbor Perspect

Microfluidic Platform to Mechanically and Biochemically Modulate Blood-Brain Barrier Function

The Clinical Use of Mindfulness Meditation for the Self-Regulation of Chronic Pain

Transport of Small Molecules through the Blood-Brain Barrier

Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion

Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio

Exosomes and the Blood−Brain Barrier: Implications for Neurological Diseases

Elucidation of Exosome Migration Across the Blood−Brain Barrier Model In Vitro

Hypoxic Glioblastoma Release Exosomal VEGF-A Induce the Permeability of Blood-Brain Barrier

Na + -Dependent Glutamate Transporters (EAAT1, EAAT2, and EAAT3) of the Blood-Brain Barrier

Blood-Brain Barrier Transport Machineries and Targeted Therapy of Brain Diseases

Transendothelial Transport and Its Role in Therapeutics

Glutamate−Glutamine Cycle and Exchange in the Placenta−Fetus Unit during Late Pregnancy

Microvesicles and Exosomes: Opportunities for Cell-Derived Membrane Vesicles in Drug Delivery

Exosomes as a Nanodelivery System: A Key to the Future of Neuromedicine?

Method for Isolation and Molecular Characterization of Extracellular Microvesicles Released from

E Identification of a Novel Mechanism of Blood−Brain Communication during Peripheral Inflammation via Choroid Plexus-Derived Extracellular Vesicles

Extracellular Vesicles of the Blood-Brain Barrier: Role in the HIV-1 Associated Amyloid Beta Pathology

Amyloid Beta Protein Gene: CDNA, MRNA Distribution, and Genetic Linkage near the Alzheimer Locus

Biomarker Potential of Brain-Secreted Extracellular Vesicles in Blood in Alzheimer's Disease. Alzheimer's Dement

Dopamine-Loaded Blood Exosomes Targeted to Brain for Better Treatment of Parkinson's Disease

Liposomes in Drug Delivery: Progress and Limitations

Biodegradable Polymeric Nanoparticles Based Drug Delivery Systems

Biodegradable Polymer Nanoparticles That Rapidly Penetrate the Human Mucus Barrier

Preparation of Biodegradable Polymer Nanoparticles by Miniemulsion Technique and Their Cell Interactions

Vitro Study of Liposomal Curcumin: Stability, Toxicity and Biological Activity in Human Lymphocytes and Epstein-Barr Virus-Transformed Human B-Cells

Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel

Brain Transport of Neurotoxin-I with PLA Nanoparticles through Intranasal Administration in Rats: A Microdialysis Study

Encapsulation of Dexamethasone into Biodegradable Polymeric Nanoparticles

A Novel Controlled Release Formulation for the Anticancer Drug Paclitaxel (Taxol®): PLGA Nanoparticles Containing Vitamin E TPGS

Exosome-Mimetic Nanoplatforms for Targeted Cancer Drug Delivery

Oral Delivery of Insulin Associated to Polymeric Nanoparticles in Diabetic Rats

Altered Lysosomal Proteins in Neural-Derived Plasma Exosomes in Preclinical Alzheimer Disease

PEGylated Polycyanoacrylate Nanoparticles as Vector for Drug Delivery in Prion Diseases

Multicenter Phase II Trial of Genexol-PM, a Cremophor-Free, Polymeric Micelle Formulation of Paclitaxel, in Patients with Metastatic Breast Cancer

Advances and Challenges of Liposome Assisted Drug Delivery

Long-Circulating Liposomes for Drug Delivery in Cancer Therapy: A Review of Biodistribution Studies in Tumor-Bearing Animals

Lactic-Co-Glycolic) Acid-Controlled-Release Systems: Experimental and Modeling Insights

Current Advances in Research and Clinical Applications of PLGA-Based Nanotechnology

Pegylated Liposomal Doxorubicin in Ovarian Cancer

Liposomal Daunorubicin (DaunoXome) for Treatment of Relapsed Meningeal Acute Myeloid Leukemia

Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Rinotecan

Emerging Data on the Use of Anti-Tumor Necrosis Factor-Alpha Medications in Pregnancy

The Design and Development of Pegfilgrastim (PEG-RmetHuG-CSF, Neulasta)

The COMBINE Study-: An Overview of the Largest Pharmacotherapy Study to Date for Treating Alcohol Dependence

A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners

Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR

Pasireotide in Acromegaly: A Review

Magnetic Resonance Imaging of High Intensity Focused Ultrasound Mediated Drug Delivery from Temperature-Sensitive Liposomes: An in Vivo Proof-of-Concept Study

Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery

Complement Activation, Immunogenicity and Immune Suppression as Potential Side Effects of Liposomes

Interactions of Liposomes and Lipid-Based Carrier Systems with Blood Proteins: Relation to Clearance Behaviour in Vivo

Immunological and Toxicological Considerations for the Design of Liposomes

Accelerated Blood Clearance of PEGylated PLGA Nanoparticles Following Repeated Injections: Effects of Polymer Dose, PEG Coating, and Encapsulated Anticancer Drug

Interactions of PLGA Nanoparticles with Blood Components: Protein Adsorption, Coagulation, Activation of the Complement System and Hemolysis Studies

Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes

Capture of Stealth Nanoparticles by the Body's Defences

Complement Activation-Related Pseudoallergy: A New Class of Drug-Induced Acute Immune Toxicity

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

The Challenges Facing Block Copolymer Micelles for Cancer Therapy: In Vivo Barriers and Clinical Translation

Biocompatible and Biodegradable Nanoparticles for Enhancement of Anti-Cancer Activities of Phytochemicals. Chin

The Exosome -A Naturally Secreted Nanoparticle and Its Application to Wound Healing

Extracellular Vesicles and Energy Metabolism

Your Body's Answer to Immune Health

CAR Exosomes Derived from Effector CAR-T Cells Have Potent Antitumour Effects and Low Toxicity

Milk-Derived Exosomes for Oral Delivery of Paclitaxel

Extracellular Membrane Vesicles as a Mechanism of Cell-to-Cell Communication: Advantages and Disadvantages

A New Approach for Loading Anticancer Drugs Into Mesenchymal Stem Cell-Derived Exosome Mimetics for Cancer Therapy

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Toward Cell-Free Therapeutic Applications

Therapeutic Application of Mesenchymal Stem Cells Derived Extracellular Vesicles for Immunomodulation

SiRNA Delivery with Exosome Nanoparticles

Exosome−Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs

A Novel Nanoparticle Drug Delivery System: The Anti-Inflammatory Activity of Curcumin Is Enhanced When Encapsulated in Exosomes

Curcumin and Cancer Cells: How Many Ways Can Curry Kill Tumor Cells Selectively?

Potential Therapeutic Effects of Curcumin, the Anti-Inflammatory Agent, against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases

Curcumin and Cancer: An "Old-Age" Disease with an

Exosomes Mediate Drug Resistance Transfer in MCF-7 Breast Cancer Cells and a Probable Mechanism Is Delivery of P-Glycoprotein

Secrete Antigen-Presenting Vesicles

Exosomes: Immune Properties and Potential Clinical Implementations

Modulation of the Immune Response Using Dendritic Cell-Derived Exosomes

Efficient Induction of Antitumor T Cell Immunity by Exosomes Derived from Heat-Shocked Lymphoma Cells

Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell Derived Exosomes

CD47-Dependent Immunomodulatory and Angiogenic Activities of Extracellular Vesicles Produced by T Cells

MicroRNAs Transfer from Human Macrophages to Hepato-Carcinoma Cells and Inhibit Proliferation

Paclitaxel Is Incorporated by Mesenchymal Stromal Cells and Released in Exosomes That Inhibit in Vitro Tumor Growth: A New Approach for Drug Delivery

Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology

Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-Inflammatory Drugs from the Nasal Region to the Brain

Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

Exosome Secreted by MSC Reduces Myocardial Ischemia/Reperfusion Injury

Mesenchymal Stem Cell-Derived Exosomes Increase ATP Levels, Decrease Oxidative Stress and Activate PI3K/Akt Pathway to Enhance Myocardial Viability and Prevent Adverse Remodeling after Myocardial Ischemia/Reperfusion Injury

Human Adipose Tissue-Derived Mesenchymal Stem Cells Secrete Functional Neprilysin-Bound Exosomes

Exosomes in Mesenchymal Stem Cells, a New Therapeutic Strategy for Cardiovascular Diseases?

Exosomes and Cardiac Repair After Myocardial Infarction

Exosome-Mediated Delivery of SiRNA in Vitro and in Vivo

Exosomes and Microvesicles: Extracellular Vesicles for Genetic Information Transfer and Gene Therapy

Exosomes Are Natural Carriers of Exogenous SiRNA to Human Cells in Vitro

Plasma Exosomes Can Deliver Exogenous Short Interfering RNA to Monocytes and Lymphocytes

Delivery of SiRNA to the Mouse Brain by Systemic Injection of Targeted Exosomes

Rapid On-Demand Extracellular Vesicle Augmentation with Versatile Oligonucleotide Tethers

Exosomes Mediate the Cellto-Cell Transmission of IFN-α-Induced Antiviral Activity

Dendritic Cell−Derived Exosomes as Immunotherapies in the Fight against Cancer

Exosomes from Bone Marrow Dendritic Cells Pulsed with Diphtheria Toxoid Preferentially Induce Type 1 Antigen-Specific IgG Responses in Naive Recipients in the Absence of Free Antigen

Molecular Characterization of Dendritic Cell-Derived Exosomes. Selective Accumulation of the Heat Shock Protein Hsc73

Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer

Dendritic Cell-Derived Exosomes Elicit Tumor Regression in Autochthonous Hepatocellular Carcinoma Mouse Models

Differential Content of Proteins, MRNAs, and MiRNAs Suggests That MDSC and Their Exosomes May Mediate Distinct Immune Suppressive Functions

Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes

Human Ebola Virus Infection Results in Substantial Immune Activation

Integrin Alphavbeta6 Is Involved in Measles Protein-Induced Airway Immune Suppression

Tolerance Induction by Exosomes from Immature Dendritic Cells and Rapamycin in a Mouse Cardiac Allograft Model

Donor-Derived Exosomes Induce Specific Regulatory T Cells to Suppress Immune Inflammation in the

Biomarker Definitions and Their Applications

Immunological Biomarkers of Tolerance in Human Kidney Transplantation: An Updated Literature Review

Serum Exosomal Protein Profiling for the Non-Invasive Detection of Cardiac Allograft Rejection

Development of Exosome Surface Display Technology in Living Human Cells

Preservation and Storage Stability of Extracellular Vesicles for Therapeutic Applications

High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients

Exosomal Tetraspanins Mediate Cancer Metastasis by Altering Host Microenvironment

Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity

CD81(+) Exosomes Play a Pivotal Role in the Establishment of Hepatitis C Persistent Infection and Contribute Toward the Progression of Hepatocellular Carcinoma

Exosome Markers Associated with Immune Activation and Oxidative Stress in HIV Patients on

Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer

Glypican-1 Identifies Cancer Exosomes and Detects Early Pancreatic Cancer

Exosomes in Cancer Development, Metastasis, and Drug Resistance: A Comprehensive Review

Collection, Storage, Preservation, and Normalization of Human Urinary Exosomes for Biomarker Discovery

Common Sense Approaches to Urinary Biomarker Study Design

Large-Scale Proteomics and Phosphoproteomics of Urinary Exosomes

Comparison of Protein, MicroRNA, and MRNA Yields Using Different Methods of Urinary Exosome Isolation for the Discovery of Kidney Disease Biomarkers

Urinary Exosomal Transcription Factors, a New Class of Biomarkers for Renal Disease

Proteomic Analysis of Urine Exosomes by Multidimensional Protein Identification Technology (MudPIT)

Nucleic Acids within Urinary Exosomes/Microvesicles Are Potential Biomarkers for Renal Disease

Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries in 2012

Exosomes Derived from Gastric Cancer Cells Activate NF-ΚB Pathway in Macrophages to Promote Cancer Progression

Let-7 MicroRNA Family Is Selectively Secreted into the Extracellular Environment via Exosomes in a Metastatic Gastric Cancer Cell Line

A Small Noncoding RNA Signature Found in Exosomes of GBM Patient Serum as a Diagnostic Tool

Exosome and MicroRNA as Novel Diagnosis Biomarkers

MiR-21: A Key Player in Glioblastoma Pathogenesis

MicroRNAs as Biomarkers for Human Glioblastoma: Progress and Potential

Exosome-Encapsulated MicroRNAs as Circulating Biomarkers for Breast Cancer

Exosomal MiRNA Profile as Complementary Tool in the Diagnostic and Prediction of Treatment Response in Localized Breast Cancer under Neoadjuvant Chemotherapy

Molecular Characterization of S. Japonicum Exosomelike Vesicles Reveals Their Regulatory Roles in Parasite-Host Interactions

Rapid Differentiation of Host and Parasitic Exosome Vesicles Using Microfluidic Photonic Crystal Biosensor

Extracellular Vesicle-Mediated Communication Within Host-Parasite Interactions

Receptor-Mediated Endocytosis of Transferrin and Recycling of the Transferrin Receptor in Rat Reticulocytes

Exosomes Facilitate Therapeutic ACS Biomaterials Science & Engineering pubs

Advances in Imaging Strategies for in Vivo Tracking of Exosomes

An Update on in Vivo Imaging of Extracellular Vesicles as Drug Delivery Vehicles

Fluorescence Molecular Tomography: Principles and Potential for Pharmaceutical Research

Current Perspectives on In Vivo Noninvasive Tracking of Extracellular Vesicles with Molecular Imaging

Imaging Extracellular Vesicles: Current and Emerging Methods

Biodistribution and Delivery Efficiency of Unmodified Tumor-Derived Exosomes

Vivo Bioluminescent Imaging (BLI): Noninvasive Visualization and Interrogation of Biological Processes in Living Animals

Visualization and in Vivo Tracking of the Exosomes of Murine Melanoma B16-BL6 Cells in Mice after Intravenous Injection

In Vivo Micro-CT Imaging of Human Mesenchymal Stem Cells Labeled with Gold-Poly-l-Lysine Nanocomplexes

Golden Exosomes Selectively Target Brain Pathologies in Neurodegenerative and Neurodevelopmental Disorders

Vivo Neuroimaging of Exosomes Using Gold Nanoparticles

Contrast Agents for Molecular Photoacoustic Imaging

Magnetic Resonance Imaging of Melanoma Exosomes in Lymph Nodes

Development and MPI Tracking of Novel Hypoxia-Targeted Theranostic Exosomes

Engineered Exosome-Mediated Near-Infrared-II Region V2C Quantum Dot Delivery for Nucleus-Target Low-Temperature Photothermal Therapy

Interaction of Heat Shock Proteins with Peptides and Antigen Presenting Cells: Chaperoning of the Innate and Adaptive Immune Responses

Heat Shock Protein 70 Surface-Positive Tumor Exosomes Stimulate Migratory and Cytolytic Activity of Natural Killer Cells

The Intracellular Interactome of Tetraspanin-Enriched Microdomains Reveals Their Function as Sorting Machineries toward Exosomes

Epstein−Barr Virus-Infected Cells Release Fas Ligand in Exosomal Fractions and Induce Apoptosis in Recipient Cells via the Extrinsic Pathway

Transfer of Extracellular Vesicles during Immune Cell-Cell Interactions

Biological Roles and Potential Applications of Immune Cell-Derived Extracellular Vesicles

Regulation of the Host Antiviral State by Intercellular Communications

Dendritic Cells in the Regulation of Immunity and Inflammation

The Ability of Extracellular Vesicles to Induce a Pro-Inflammatory Host Response

Role of Tumor Microenvironment in Tumorigenesis

Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis

Extracellular Vesicles: Satellites of Information Transfer in Cancer and Stem Cell Biology

The Tumour-Induced Systemic Environment as a Critical Regulator of Cancer Progression and Metastasis

Tumor-Associated Macrophages: From Mechanisms to Therapy

Malaria Parasite DNA-Harbouring Vesicles Activate Cytosolic Immune Sensors

Exosomes and Other Extracellular Vesicles in Host-Pathogen Interactions

Cancer Vaccines: Accomplishments and Challenges

Increasing Vaccine Potency through Exosome Antigen Targeting

Molecules Relevant for T Cell-Target Cell Interaction Are Present in Cytolytic Granules of Human T Lymphocytes

Cytotoxic T Lymphocyte Granules Are Secretory Lysosomes, Containing Both Perforin and Granzymes

Characterization of Exosomes Derived from Toxoplasma Gondii and Their Functions in Modulating Immune Responses

A Basis for Vaccine Development: Comparative Characterization of Haemophilus Influenzae Outer Membrane Vesicles

The Role of Angiogenesis in Cancer Treatment

Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment

Exosome: Function and Role in Cancer Metastasis and Drug Resistance

Prognostic Role of Circulating Exosomal MiRNAs in Multiple Myeloma

Prognostic Role of Circulating Exosomal MiR-425−3p for the Response of NSCLC to Platinum-Based Chemotherapy

Endothelial Expression of Autocrine VEGF upon the Uptake of Tumor-Derived Microvesicles Containing Oncogenic EGFR

Intercellular Transfer of the Oncogenic Receptor EGFRvIII by Microvesicles Derived from Tumour Cells

Glioma-Derived MiRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells

Extracellular Vesicles in Angiogenesis

Blood-Based Tumor Biomarkers in Lung Cancer for Detection and Treatment

NCT03581435. A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients (EXOGBC001)

The Functions and Clinical Applications of Tumor-Derived Exosomes

Exosomes in Gastric Cancer: Roles, Mechanisms, and Applications

Effect of Exosomal MiRNA on Cancer Biology and Clinical Applications

Suppression of Endothelial Cell Migration by Tumor Associated Macrophage-Derived Exosomes Is Reversed by Epithelial Ovarian Cancer Exosomal LncRNA

Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now? Front

Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Liver Fibrosis

Mesenchymal-Stem-Cell-Derived Exosomes Accelerate Skeletal Muscle Regeneration

Focus on Extracellular Vesicles: Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles

First Characterization of Human Amniotic Fluid Stem Cell Extracellular Vesicles as a Powerful Paracrine Tool Endowed with Regenerative Potential

Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed against the Insulin-like Growth Factor Type I Receptor in Malignant Astrocytomas

Adjuvant Enoxaparin Therapy May Decrease the Incidence of Postoperative Thrombotic Events Though Does Not Increase the Incidence of Postoperative Intracranial Hemorrhage in Patients with Meningiomas

Adipose Mesenchymal Stem Cell-Derived Exosomes Promote Cell Proliferation, Migration, and Inhibit Cell Apoptosis via Wnt/β-Catenin Signaling in Cutaneous Wound Healing

Fetal Dermal Mesenchymal Stem Cell-Derived Exosomes Accelerate Cutaneous Wound Healing by Activating Notch Signaling

The Antidiabetic Effect of Mesenchymal Stem Cells Is Unrelated to Their Transdifferentiation Potential but to Their Capability to Restore Th1/Th2 Balance and to Modify the Pancreatic Microenvironment

Epidermal Growth Factor Increases Insulin Secretion and Lowers Blood Glucose in Diabetic Mice

Extracellular Vesicles in Type 2 Diabetes Mellitus: Key Roles in Pathogenesis, Complications, and Therapy

Exosome-Like Vesicles as New Mediators and Therapeutic Targets for Treating Insulin Resistance and β-Cell Mass Failure in Type 2 Diabetes Mellitus

The Role of Extracellular Vesicles in β-Cell Function and Viability: A Scoping Review

Exosomes as Biomarkers and Therapeutic Tools for Type 1 Diabetes Mellitus

Exosomes as Messengers Between Mother and Fetus in Pregnancy

Placenta-Derived Exosomes: Potential Biomarkers of Preeclampsia

Placental Exosomes as Early Biomarker of Preeclampsia: Potential Role of Exosomal MicroRNAs Across Gestation

Placental Exosomes in Normal and Complicated Pregnancy

The Epidemiology of Obesity: A Big Picture

XXXX, XXX, XXX−XXX Metabolism in Mice

The Clinical Potential of Circulating MicroRNAs in Obesity

Elevated Levels of Circulating Exosome in COPD Patients Are Associated with Systemic Inflammation

Exosomal MicroRNA-21 Derived from Bronchial Epithelial Cells Is Involved in Aberrant Epithelium-Fibroblast Cross-Talk in COPD Induced by

Inflammatory Cytokines and Immune System Modulation by Aerobic versus Resisted Exercise Training for Elderly

Immunological Responses against SARS-Coronavirus Infection in Humans

COVID-19, Immune System Response, Hyperinflammation and Repurposing Antirheumatic Drugs

A Single-Cell Atlas of the Peripheral Immune Response in Patients with Severe COVID-19

Longitudinal Characteristics of Lymphocyte Responses and Cytokine Profiles in the Peripheral Blood of SARS-CoV-2 Infected Patients

Immunomodulatory Potential of

The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients

Adult Mesenchymal Stem Cells and Their Exosomes: Sources, Characteristics, and Application in Regenerative Medicine

Cell Responses to Viral Infections -Opportunities for Peptide Vaccination

Anti-Viral CD8 T Cells and the Cytokines That They Love

CD4(+) T Cell Differentiation in Chronic Viral Infections: The Tfh Perspective

The CD8 T Cell Response to Respiratory Virus Infections